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Abbreviations: 
AML   Acute Myeloid Leukemia 
ALL   Acute Lymphoid Leukemia 
APL   Acute Promyelocytic Leukemia 
BR-LZ  Basic Region-Leucine Zipper 
CLP   Common Lymphoid Progenitor 
C/EBP  CCAAT Enhancer Binding Protein 
CHCA  -Cyano-4-Hydroxy Cinnamic Acid 
CML   Chronic Myeloid Leukemia 
DAPI   4, 6-Diamino-2-Phenylindole Dihydrochloride 
DTE   Dithioerythritol 
DHB   2,5-Dihydroxy-Benzoicacid 
DMEM  Dulbecco´s Modified Eagle Medium 
DMSO  Dimethylsulfoxide 
FAB   French American British Classification 
FBS   Foetal Bovine Serum 
FACS  Fluorescence Activated Cell Sorting 
GMP   Granulocyte/Macrophage Progenitor 
GCSFR  Granulocyte Colony Stimulating Factor Receptor 
HSC   Hematopoietic Stem Cell 
IB   Immunoblot 
IEF   Isoelectric Focussing 
IP   Immunoprecipitation 
Ivt   In-vitro Translated 
LC   Liquid Chromatogrphy 
MALDI  Matrix Assisted Laser Desorption Ionisation 
MEP   Megakaryocyte/Erythroid Progenitor 
MS   Mass Spectrometry 
NK   Normal Karyotype 
Nbm   Normal Bone Marrow 
PBS   Phosphate Buffered Saline 
PMF   Peptide Mass Fingerprinting 
pI   Isoelectric Point 
PIN1   Peptidyl-prolyl cis/trans isomerase 
RA   Retinoic Acid 
SDS   Sodium Dodecyl Sulphate 
TE   Transactivation Element 
TAD   Transactivation Domain 
TOF   Time of Flight  
USF   Upstream Stimulatory Factor 
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1. Introduction 
1.1 Hematopoiesis 
  Hematopoiesis is the process by which mature blood cells of different lineages 
develop from pluripotent hematopoietic stem cells (HSCs) through a highly 
organized hierarchy of successive differentiation events (Figure 1).  
Hematopoiesis takes place in several distinct anatomical sites during mouse 
embryogenesis. Primitive blood cells are first identifiable in the blood islands of 
the embryonic yolk sac at embryonic day 7.5 of gestation.  The aorta gonad 
mesonephros (AGM) and fetal liver represent the principal intraembryonic fetal 
hematopoietic organs (Houssaint, 1981). From birth and throughout adult life, 
all mature blood cells are produced in the bone marrow.                   
  Hematopoietic stem cells (HSCs) constitute 0.05% of mouse bone marrow 
cells, and can be divided into three distinct populations: long-term self-renewing 
HSCs, short-term self-renewing HSCs, and multipotent progenitors without 
detectable self-renewable potential (Reya et al., 2001). The multipotent 
progenitors give rise to common lymphoid progenitors (CLPs; the precursors for 
lymphoid cells) and common myeloid progenitors (CMPs). The CMPs give rise 
to granulocyte/macrophage progenitors (GMPs) and megakaryocyte/erythroid 
progenitors (MEPs). The GMPs develop into granulocytes, monocytes and 
dendritic cells while MEPs develop into platelets and erythrocytes (Figure 1).  
1.2 Acute Myeloid Leukemia  
  The main focus in cancer research has been identification of oncogenes as well 
as tumor suppressors and identification of the pathways coordinated by 
oncogenes and tumor suppressors. It is proposed that a block in the 
differentiation programme from precursor to mature cells can cause cancer. 
Recent evidence suggests that disruption of myeloid transcription factors as 
being important step in acute myeloid leukemia. 
12
Figure 1. Hematopoietic lineage diversification: Development of hematopoietic stem cell 
to various lineages  (Reya et al., 2001) 
  Leukemia is a common term used for a group of hematological malignancies 
characterized by accumulation of hematopoietic precursor cells, which fail to 
undergo terminal differentiation (Tenen, 2003). Leukemia is classified as acute 
and chronic based on how quickly it progresses. Acute leukemia is fast growing 
and can overrun the body within a few weeks or months, while chronic leukemia 
is slow growing and progresses in years. According to the type of lineage which 
is affected, leukemia is classified as myeloid and lymphoid. The four major 
types of leukemia are: 
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• Acute Myeloid Leukemia (AML) 
• Chronic Myeloid Leukemia (CML) 
• Acute Lymphocytic Leukemia (ALL) 
• Chronic Lymphocytic Leukemia (CLL) 
 According to French-American-British (FAB) classification, AML is divided 
into 9 subtypes based on the morphological appearance of the blasts and their 
reactivity with biochemical stains (Bennett et al., 1976; Lowenberg et al., 1999).  
The subtypes of the FAB classification of AML are represented in Table 1.   
Table 1. French-American-British (FAB) classification of AML 
FAB 
subtype
Description Associated 
translocations 
and rearrangements
M0 
Acute myeloblastic leukemia with 
minimal differentiation inv(3q26), t(3;3) 
M1 
Acute myeloblastic leukemia without 
maturation
M2 Acute myeloblastic leukemia with 
maturation
t(8;21), t(6;9) 
M3 Acute promyelocytic leukemia t(15;17), t(11;17), t(5;17)
M4 Acute myelomonocytic leukemia 11q23, inv(3q26), t(3;3), 
t(6;9) 
M4E0 Acute myelomonocytic leukemia 
with abnormal eosinophils 
inv(16), t(16;16) 
M5 Acute monocytic leukemia 11q23, t(8;16) 
M6 Erythroleukemia 
M7 Acute megakaryocytic  leukemia t(1;22) 
Adapted from Lowenberg B et al, New England Journal of Medicine 1999. 
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  Recent findings show that cell cycle control and the regulation of 
differentiation programme are two closely related events which can have crucial 
role in tumorigenesis. More recently, the concept of the existence of a leukemic 
stem cell (LSCs) has been proposed (Huntly and Gilliland, 2005). The formation 
of LSCs, which exhibit little differentiation capacity but fail to differentiate into 
mature cells, is thought to be a result of somatic mutations in HSCs or in 
committed progenitors.  The mutations vary from chromosomal translocations 
leading to fusion proteins (eg. AML1/ETO, PML/RAR) to point mutations in 
critical transcription factors (Rosenbauer et al., 2005); (Passegue et al., 2003; 
Zhang and Rosen, 2006). Figure 2 compares the cellular hierarchy of normal and 
malignant hematopoiesis (leukemia).  
1.3 Transcription Factors in Hematopoiesis
   Transcription factors are specialized nuclear proteins that can bind specifically 
to their DNA binding site and activate transcription. A major factor which 
Figure 2.  Cellular hierarchy of normal and malignant hematopoiesis  (Huntly BJ and 
Gilliland DG, Nature Review Cancer, 2005) 
LSC
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determines the cell fate in hematopoiesis is the interplay between tissue specific 
transcription factors, which in turn, modulate a specific set of genes necessary 
for differentiation to a specific lineage (Cantor and Orkin, 2001; Tenen et al., 
1997); (Lutterbach and Hiebert, 2000). Transcription factors play an important 
role in regulating major steps of hematopoiesis, such as differentiation, 
proliferation and survival. Several of those transcription factors have narrow 
expression patterns in that they are limited to a few hematopoietic lineages. 
  The major transcription factors involved in granulopoiesis are runt-related 
transcription factors (RUNX1; also known as AML1) (Okuda et al., 1996), 
stem-cell leukemia factor (SCL, also known as Tal-1) (Shivdasani et al., 1995), 
PU.1 (Klemsz et al., 1990), CCAAT/enhancer-binding proteins (in particular 
C/EBP, C/EBP, C/EBP) (Tanaka et al., 1995; Yamanaka et al., 1997; Zhang 
et al., 1997), interferon-regulatory factor 8 (IRF8) (Holtschke et al., 1996) and 
growth-factor independent 1 (GFI1) (Hock et al., 2003). The major transcription 
factors in granulopoiesis and the critical steps they regulate are depicted in 
figure 3. 
Figure 3.  Role of transcription factors in granulopoiesis (Rosenbauer F and Tenen DG, 
Nature Reviews Immunology, 2007)              
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  Transcription factors such as RUNX1 and SCL are the critical factors that 
orchestrate formation of hematopoietic stem cells from mesoderm during 
embryogenesis. Mice that are deficient for either RUNX1 or SCL die during 
embryogenesis and lack hematopoiesis (Okuda et al., 1996; Shivdasani et al., 
1995). The function of PU.1 in granulopoiesis is the development of CMPs from 
HSCs (Dakic et al., 2005; Iwasaki et al., 2005; Scott et al., 1997). Mice that lack 
PU.1 show complete absence of macrophages (McKercher et al., 1996; Scott et 
al., 1997). Studies show that high PU.1 levels support the production of 
macrophages, while low PU.1 level support granulocyte development (Dahl et 
al., 2003; Rosenbauer et al., 2004).  
    The role of C/EBP in granulopoiesis was underlined by the finding that 
nonconditional targeted disruption of C/EBP results in a selective early block 
in granulocytic maturation, without affecting other hematopoietic lineages 
(Zhang et al., 1997). C/EBP conditional knock-out mice show a selective block 
in the transition from the CMP to GMP stage of granulopoiesis and an increase 
in HSC self renewal (Zhang et al., 2004). This study points out that C/EBP is 
necessary for CMP to GMP transition as well as in regulating the self renewal of 
HSC compartment of bone marrow during granulopoiesis.  The concept of 
C/EBP as granulocyte specific transcription factor is questioned by the finding 
that fetal liver from C/EBP-/- mice also lack mature macrophages and 
macrophage progenitors, suggesting that C/EBP can have crucial role in the 
development of macrophages (Heath et al., 2004). 
   The role of IRF8 (interferon-regulatory factor 8) in granulopoiesis is 
underlined by the finding that IRF8 knock-out mice had a reduced number of 
macrophages and increased number of granulocytes, suggesting that IRF8 favors 
macrophage development (Holtschke et al., 1996). After GMP development, 
transcription factors necessary for granulopoiesis are GFI1 and C/EBP. Mice 
that lack GFI1 as well as C/EBP exhibit abnormal granulopoiesis beyond the 
promyelocyte stage suggesting the importance of these factors during the final 
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stages of granulopoiesis (Yamanaka et al., 1997); (Hock et al., 2003). GFI1 has 
been shown to repress monocyte specific genes (Hock et al., 2003). The function 
of C/EBP in the final stage of granulopoiesis is the regulation of genes 
necessary for the development of secondary and tertiary granule proteins such as 
lactoferrin and gelatinase (Yamanaka et al., 1997).
1.4 The C/EBP family 
  The CCAAT/enhancer-binding proteins (C/EBPs)  are a family of transcription 
factors that include six members C/EBP, C/EBP, C/EBP, C/EBP, C/EBP
and C/EBP (Ramji and Foka, 2002); (Akira et al., 1990); (Cao et al., 1991);  
(Roman et al., 1990). Except for C/EBP, which lacks the basic region, each 
protein contains similar basic region and leucine zipper sequences at its C-
terminus, which mediate DNA binding and dimerization, respectively.  The 
C/EBP proteins form leucine zipper mediated homodimers as well as 
heterodimers with other C/EBP members (Ramji and Foka, 2002); (Akira et al., 
1990); (Cao et al., 1991);  (Roman et al., 1990);  (Ryden and Beemon, 1989). 
The dimer resembles an inverted Y shaped structure in which each arm of the Y 
is made of the basic region, which binds to palindromic DNA sequence in the 
DNA major groove.  The predicted structure of a C/EBP bZIP dimer bound to 
its cognate DNA site is depicted in figure 4 (Johnson, 2005; Miller et al., 2003).
  The N-terminal portion of each protein contains effector domains that mediate 
transcriptional activation, repression and autoregulatory functions. The 
expression pattern of each C/EBP varies in different tissues pointing out to the 
fact that each member could have specific roles in each cell type. In 
hematopoiesis, the C/EBP members shown to have specific function are 
C/EBP, C/EBP and C/EBP. C/EBP is necessary for early granulocytic 
differentiation i.e., from hematopoietic stem cell to promyelocyte and C/EBP is 
necessary for terminal granulocyte differentiation i.e., from promyelocyte to 
mature neutrophil (Theilgaard-Monch et al., 2005). C/EBP is necessary for 
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granulopoiesis in  emergency conditions such as fungal infection or cytokine 
stimulation (Hirai et al., 2006).  
1.5 C/EBP  
  CCAAT/enhancer-binding protein alpha (C/EBP) is the first leucine- zipper 
(bZIP) group of transcription factors discovered (Landschulz et al., 1988). 
C/EBP was identified originally as a heat stable protein present in  rat liver 
nuclei and having sequence specific DNA binding activity (Graves et al., 1986; 
Johnson et al., 1987). The DNA sequences to which C/EBP binds are the 
“CCAAT homology” common to many promoters of genes that encode mRNA, 
and the “enhancer core homology” common to many viral enhancers. These 
findings point out the role of C/EBP as  a transcriptional regulatory protein 
(Johnson et al., 1987). 
  C/EBP is highly expressed in a variety of tissues including liver, lung, 
placenta, adipose tissue, intestine, mammary gland, skin and peripheral blood 
mononuclear cells (Birkenmeier et al., 1989); (Antonson and Xanthopoulos, 
1995). Human C/EBP is encoded by an intronless gene and is located at 
chromosome band 19q13.1 (Hendricks-Taylor et al., 1992). 
TTGCG  AA
A 
G
T
C
T
C
Figure 4. The predicted structure of a C/EBP bZIP dimer bound to its cognate DNA site 
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1.5.1. Domains of C/EBP
  C/EBP contains a transactivation domain, a DNA binding basic region and a 
leucine zipper dimerization domain. The leucine zipper is a heptad of leucine 
repeats that intercalate with repeats of the dimer partner, forming a coiled coil of 
alpha-helices in parallel orientation (Agre et al., 1989; Landschulz et al., 1988; 
Vinson et al., 1993). The basic region, which contacts the DNA, is a stretch of 
approximately 20 amino acids,  upstream of the leucine zipper (Johnson, 1993).
The N-terminal domain which is responsible for transcriptional activation and/or 
repression consists of three transactivation elements - TE-I, TE-II and TE-III.   
Figure 5. Different domains of C/EBP and proteins regulated by C/EBP (Claus 
Nerlov, Nature Reviews Cancer, 2004) 
  The C/EBP mRNA gives rise to two different translational products by using 
two different AUGs within the same open reading frame (Lin F et al, 1993, 
Ossipow V et al, 1993): a full length 42 kD protein (p42) and a truncated 30 kD 
version (p30), which in contrast to p42 lacks transactivation elements TE-I and 
TE-II.  
1.5.2 Distribution of C/EBP functions 
  C/EBP directly activates transcription from lineage-specific promoters.   
C/EBP  has been shown to regulate a number of genes mainly in 
BR-LZ
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granulopoiesis, adipogenesis, and in tissues such as lung, liver, skin and  
mammary epithelial cells (Ramji and Foka, 2002). Beyond acting as a classical 
transcription factor, C/EBP has been shown to interact with and/or regulate a 
number of proteins. The transactivation elements  TE-I and TE-II of C/EBP
have been found to interact with the basal transcriptional apparatus, TBP/TFIIB 
(Nerlov and Ziff, 1995). It has been found that these elements are necessary for 
E2F repression during granulopoiesis and adipogenesis (Porse et al., 2001) as 
well as for interaction with histone acetyl transferases, CBP/p300 (Kovacs et al., 
2003); (Schwartz et al., 2003). The transactivation element TE-III is responsible 
for  recruitment of chromatin-remodelling complexes,  SW1/SNF (Pedersen et 
al., 2001). It is also found that TE-III is responsible for binding and inhibition of 
CDK2/4 (Wang et al., 2001). 
  The  bZip domain is shown to interact with E2F (Johansen et al., 2001) and  c-
Jun (Rangatia et al., 2002) as well as PU.1, ETS1, GATA1, RUNX1 (McNagny 
et al., 1998; Reddy et al., 2002);  (Zhang et al., 1996a); (Yamaguchi et al., 
1999).  
1.5.3 C/EBP –mechanisms of action  
  One of the most important functions of C/EBP is its role in cell cycle. 
C/EBP induces cell cycle arrest in a variety of tissues (Johnson, 2005; 
McKnight, 2001). There are different mechanisms proposed for the C/EBP
mediated cell cycle arrest. The initial studies  investigating the C/EBP
mediated cell cycle arrest revealed that C/EBP interacts with the cyclin 
dependent kinase (CDK) inhibitor p21 in developing liver by protein-protein 
interaction (Timchenko et al., 1996). It is observed that p21 levels increase 20 
fold during C/EBP induction and p21 binds to and inhibits the kinase activity 
of CDK4, CDK6 and CDK2.  Another mechanism proposed for C/EBP
mediated cell cycle arrest is its interaction with cyclin dependent kinase CDK2 
and CDK4 (Wang et al., 2001).   
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  The mechanism that has gained the most acceptance is the C/EBP mediated 
repression of the E2F transcription factors. The E2F group of transcription 
factors regulates genes required for cell cycle progression.  Experiments in 
murine fibroblast cell lines showed that C/EBP inhibits proliferation of 
fibroblast cells and  that C/EBP is present in a complex that binds to E2F sites 
in genes such as dihydrofolate reductase (DHFR) and E2F-1 that are upregulated 
during the G1-S transition (Slomiany et al., 2000). C/EBP also represses 
transcription from reporter constructs containing the DHFR or E2F1 promoters. 
Porse et al provided further proof for the E2F repression model, deciphering 
domains of C/EBP required for repression of E2F driven transcription (Porse et 
al., 2001). They showed that transactivation element (TE-I) at the N-terminus as 
well as residues residing on the non-DNA binding face of C/EBP basic region 
as the critical domains for the cell cycle inhibitory effect of C/EBP. Later 
studies showed that the  bZip domain of C/EBP  is able  to interact with   E2F 
(Johansen et al., 2001).  
  All the above studies show that the mechanism by which C/EBP inhibits cell 
proliferation seems to differ from cell type to cell type. Findings from myeloid 
systems support the concept that C/EBP mediated E2F repression is the major 
pathway that mediates cell cycle exit and differentiation in granulopoiesis (Porse 
et al., 2001); (D'Alo et al., 2003); (Porse et al., 2005); (Rosenbauer and Tenen, 
2007). 
1.5.4 C/EBP in normal hematopoiesis. 
Granulocytes play a major role in host defense, and patients with granulocyte 
deficiency are extremely vulnerable to bacterial infection. Unlike long-lived 
lymphocytes, granulocytes have a short lifespan, necessitating a tight 
relationship between supply and demand. After production and release by the 
bone marrow, the life span of neutrophils is only 8 hours. Mature neutrophils are 
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unable to undergo cell division. The factors that play critical role in 
granulopoiesis have been a major research focus in hematology. 
  Studies in the early 1990s focused on the role C/EBP in the differentiation 
programmes in tissues such as adipocyte, liver, lung etc. Later, the role of 
C/EBP in granulopoiesis was elucidated by the finding that a large number of 
myeloid genes contain C/EBP binding sites in their promoters (Tenen et al., 
1997).  The role of C/EBP in granulopoiesis was underlined by the finding that  
targeted disruption of C/EBP results in a selective early block in granulocytic 
maturation, without affecting other hematopoietic lineages (Zhang et al., 1997). 
Even though C/EBP is expressed at low levels in hematopoietic stem cell 
(HSC), it is found that C/EBP is specifically upregulated during granulocytic 
differentiation. The relative levels of C/EBP during different stages of 
granulopoiesis are depicted in figure 6 (Akashi et al., 2000; Bjerregaard et al., 
2003).   
+
+    Denotes relative C/EBP expression
CMP
GMP
LT-HSC ST-HSC
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Figure 6. Relative levels of C/EBP in different stages of granulopoiesis  
  Radomska et al., have shown that conditional expression of C/EBP alone is 
sufficient to trigger neutrophilic differentiation (Radomska et al., 1998). Primary 
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CD34+ cells isolated from human bone marrow differentiate into granulocytes 
when transduced with a retroviral vector expressing C/EBP (Iwama et al., 
2002). C/EBP conditional knock-out mice show a selective block in the 
transition from the CMP to the GMP stage of granulopoiesis (Zhang et al., 
2004). Loss of C/EBP leads to an increase in HSC self renewal compared to 
that of wild type HSC. 
   In the hematopoietic system, a number of  C/EBP target genes have been 
found, including a number of primary granule protein genes (Oelgeschlager et 
al., 1996); (Iwama et al., 1998). C/EBP was also described to regulate the 
genes encoding the receptors for the granulocytic growth factors- granulocyte 
colony-stimulating factor (G-CSF) and interleukin 6 (IL-6) (Smith et al., 1996; 
Zhang et al., 1997; Zhang et al., 1998). However, knock-out studies of these 
factors suggested that these were not the critical target genes, since disruption of 
one or more growth factors failed to show the complete granulocyte 
differentiation block observed in C/EBP knock-out mice (Liu et al., 1996); (Liu 
et al., 1997). Recently it has been shown that C/EBP regulates microRNA-223 
during granulopoiesis (Fazi et al., 2005). Induction of C/EBP in myeloid 
differentiation models results in the displacement of NFI-A from the miR-223 
promoter by C/EBP and concomitant upregulation of miR-223 and 
granulopoiesis. It was shown that downregulation of c-Jun expression by 
C/EBP is important for granulocytic lineage commitment (Rangatia et al., 
2002).  
  Recent studies suggest that inhibition of E2F pathways by C/EBP is the most 
critical step in granulopoiesis (D'Alo et al., 2003; Porse et al., 2005; Porse et al., 
2001; Rosenbauer and Tenen, 2007). Transactivation element-I (TE-I) at the N-
terminus as well as residues residing on the non-DNA binding face of C/EBP
basic region are the critical domains for the E2F repression by C/EBP (Porse et 
al., 2001). Mutation of either results in loss of C/EBP inhibition of E2F, which 
results in block of granulocytic differentiation (D’Alo F et al, 2003). Another 
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study showed that inhibition of E2F leads to downregulation of E2F target gene 
c-Myc (Johansen et al., 2001). Knock-in mice with a targeted mutation in the 
C/EBP-E2F interaction domain (the BRM2 mutation) displayed a block in 
granulocytic differentiation and expansion of myeloid progenitor population 
(Porse et al., 2005). All these studies suggest that C/EBP mediated repression 
of E2F pathways is a major event in granulopoiesis.
1.6 C/EBP and leukemia 
    Recent studies show that C/EBP function is impaired by various 
mechanisms in leukemia. The first report of deregulation of C/EBP was shown 
by AML1/ETO, the product of the t(8;21) translocation (Westendorf et al., 
1998).  C/EBP mRNA was found suppressed by AML1/ETO fusion protein 
both in vitro and in vivo (Pabst et al., 2001a). AML-M2 patients with t(8;21) 
show up to six fold less C/EBP mRNA than AML-M2 patients with normal 
karyotype (Pabst et al., 2001a). BCR-ABL, the product of the t(9;22) 
translocation in chronic myeloid leukemia (commonly known as Philadelphia 
chromosome) has been found to inhibit C/EBP translation by interaction of the 
poly(rC)-binding protein hnRNP E2 with CEBPA mRNA (Perrotti et al., 2002). 
   
  Another fusion protein that was found to downregulate C/EBP in AML was 
AML1-MDS-EVI1 (AME), the product of the t(3;21) translocation (Helbling et 
al., 2004). AME was shown to induce expression of the RNA binding protein, 
calreticulin. Calreticulin interacts with GCN repeats within the C/EBP  mRNA 
and inhibits the translation of C/EBP  protein (Helbling et al., 2004). Similarly, 
CBFB-SMMHC fusion protein found in AML patients with inv(16) has been 
shown to upregulate calreticulin expression and inhibit C/EBP (Helbling et al., 
2005). 
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De-regulation of C/EBP in leukaemia
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
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  Figure 7. Deregulation of C/EBP in leukemia: C/EBP as tumor suppressor 
  PMR-RAR, the leukemic fusion protein observed in acute promyelocytic 
leukemia deregulates C/EBP by repressing C/EBP promoter activity (Guibal 
et al., 2005). C/EBP mRNA is repressed by FLT3/ITD signaling in vitro in 
32D myeloid cells (Zheng et al., 2004). This repression can be overcome by 
treatment with CEP-701, a FLT3 inhibitor (Zheng et al., 2004). It is found that 
activation of FLT3 in AML inhibits C/EBP  function by ERK1/2-mediated 
phosphorylation of C/EBP  (Radomska et al., 2006). Also, hypermethylation 
was detected in the CEBPA promoter in AML patients (Chim et al., 2002). All 
these studies show that the myeloid master regulator C/EBP is deregulated in 
acute myeloid leukemia in different ways.  
1.6.1 C/EBP mutations in AML 
  The role of C/EBP  as a tumor suppressor gene is underlined by the discovery 
that C/EBP  is mutated in acute myeloid leukemia (Pabst et al., 2001b);  
(Gombart et al., 2002). C/EBP is mutated in around 9 % of AML patients 
(Nerlov, 2004; Rosenbauer and Tenen, 2007). The mutations reported in 
26
C/EBP are point mutations at basic region leucine zipper and frame shift 
mutation at N- terminus resulting in  a 30 kD form of C/EBP initiated from the 
second AUG (Pabst et al., 2001b). The mutant forms of C/EBP observed in 
AML are depicted in figure 8.  
Figure 8. Wild type and mutant forms of C/EBP in AML
      
1.6.2 C/EBP-p30  
  The C/EBP mRNA gives rise to two different translation products based on 
two different AUGs in the same open reading frame. The 30 kD form of 
C/EBP, C/EBP-p30 lacks the N-terminal transactivation domain but retains 
the C-terminal DNA-binding domain. C/EBP-p30 shows decreased DNA 
binding and is deficient in transactivation potential (Pabst et al., 2001b). It has 
been reported previously that C/EBP-p30 lacks antimitotic activity (Lin et al., 
1993). Conditional expression of the C/EBP-p30 in myeloid precursor cells 
fails to induce granulocytic differentiation (Pabst et al., 2001b).  Interestingly, 
C/EBP-p30 inhibits DNA binding  and transactivation of the wild type  protein 
in a dominant negative manner (Pabst et al., 2001b). Expression of the dominant  
negative C/EBP-p30 form  in human hematopoietic progenitor CD34+ cells 
inhibits granulocytic differentiation (Schwieger et al., 2004).  
BR-LZ C 35TE-I TE-II TE-III
N 
1 
C/EBP
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  The mechanism by which C/EBP-p30 exerts its dominant negative function is 
not understood. It was suggested initially that C/EBP-p30 could be forming 
heterodimers with wild type C/EBP. A recent report shows that C/EBP-p30 
modified at the leucine zipper, which is unable to form heterodimers with 
C/EBP-p42, still exhibits dominant negative properties over the wild type 
protein (Cammenga et al., 2005). The first study that identified C/EBP
mutations failed to detect C/EBP-p42/C/EBP-p30 heterodimers (Pabst et al., 
2001b). One recent study showed that C/EBP-p30 plays transcriptional 
regulatory roles distinct from C/EBP-p42 in a hepatocyte cell line (Wang et al., 
2007). This study suggests that C/EBP-p30 could regulate a unique set of genes 
distinct from wild type C/EBP.  All these findings suggest that the mechanism 
with which C/EBP-p30 modulates its functions could be by upregulating a 
unique set of genes that are different from C/EBP-p42 and not by forming 
heterodimers with C/EBP-p42. 
  In order to identify the role of C/EBP-p30 in leukemogenesis, a mouse line 
carrying a germline Cebpa mutation  resulting in the specific ablation of the p42 
isoform of C/EBP was generated (Kirstetter et al., 2008). This was 
accomplished by introducing a nonsense codon between the two ATG codons 
functioning as tranlational start sites for the p42 and p30 forms. Mice 
heterozygous for C/EBP-p30 developed normally and didn‘t display any 
hematopoietic abnormalities. Mice homozygous for C/EBP-p30 survived until 
adulthood. These animals showed defects in differentiation of myeloid 
progenitors in the bone marrow at weaning.  These animals developed AML in 
12 months with massive invasion of liver and spleen. All these findings, the 
patient data and the genetic loss of function studies in mice show that loss of 
C/EBP expression or function in leukemic blasts leads to a block in myeloid 
cell differentiation. This supports the concept that C/EBP  disruption is one of 
the central events in acute myeloid leukemia (Rosenbauer and Tenen, 2007). 
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1.7 Regulation of C/EBP  
1.7.1 C/EBP and dimerization 
    The C/EBP protein can form a homodimer with another C/EBP protein as 
well as heterodimer with other members of the CEBP family (Ramji and Foka, 
2002); (Akira et al., 1990); (Cao et al., 1991);  (Roman et al., 1990);  (Ryden 
and Beemon, 1989). It has been observed that heterodimerization could 
potentially alter several functional activities of C/EBP protein, including DNA 
binding, transactivation potential, responsiveness to signaling pathways, and the 
ability to cooperate with other transcription factors. Heterodimers between 
C/EBP members possess regulatory activities that are distinct from homodimers. 
C/EBP-C/EBP heterodimers have been observed in liver nuclear extracts and 
monocytic cells (Ossipow et al., 1993; Pan et al., 1999). Heterodimerization of 
C/EBP with ATF-2 results in decreased activation of transcription driven from 
consensus C/EBP-binding sites (Shuman et al., 1997). One study shows that 
heterodimerization of C/EBP with c-Jun blocks C/EBP DNA binding 
(Rangatia et al., 2003). These studies show that dimerization of C/EBP with 
different proteins can modulate its functions. 
1.7.2 C/EBP and post translational modifications 
    C/EBP has been shown to be phosphorylated at serine 21 by extracellular 
signal-regulated kinases 1 or 2 (ERK1/2)(Ross et al., 2004). This 
phosphorylation has been shown to block granulopoiesis. It is shown that ras 
signaling enhances the activity of C/EBP to induce granulocytic differentiation 
in mouse by phosphorylation of C/EBP at serine 248 (Behre et al., 2002). 
PP2A mediated dephosphorylation at serine 193 mediated by PI3K/Akt pathway 
has been shown to block the growth inhibitory effect of C/EBP (Wang et al., 
2004). Also,  glycogen synthase kinase 3 (GSK3), has been found to 
phosphorylate C/EBP on T222, T226, and S230 in vivo (Ross et al., 1999). 
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Another post translational modification reported for C/EBP is sumoylation 
(Subramanian et al., 2003).  
1.7.3 Auto regulation of C/EBP mRNA 
    C/EBP mRNA is autoregulated in mouse as well as human via different 
mechanisms. Activation of the murine promoter by direct binding of C/EBP
was shown to increase the transactivation up to 3 fold (Christy et al., 1991; 
Legraverend et al., 1993). It is shown that USF (upstream regulatory factor) is 
also critical for the murine C/EBP promoter activity (Legraverend et al., 1993). 
Human C/EBP protein can activate its own promoter without direct binding, 
but by stimulating USF to bind to the consensus USF binding site in the C/EBP
promoter (Timchenko et al., 1995). 
1.7.4 C/EBP and protein-protein interaction 
    An important level of transcription factor regulation is through protein-protein 
interaction. Such interactions have been shown to be important in hematopoiesis 
(Stopka et al., 2005). C/EBP has been shown to physically interact with E2F1 
(Johansen et al., 2001). Knock-in mice with a targeted mutation in the C/EBP-
E2F interaction (the BRM2 mutation) displayed block in granulocytic 
differentiation and expansion of myeloid progenitor population (Porse et al., 
2005). Direct physical interaction of C/EBP with PU.1 is important for PU.1 
inactivation by C/EBP to drive granulocytic differentiation (Reddy et al., 
2002). Protein-protein interaction of C/EBP  and c-Jun have been shown to be 
essential in granulopoiesis (Rangatia et al., 2002). C/EBP  has been also shown 
to interact with several other proteins including  ETS1, GATA1, RUNX1 
(McNagny et al., 1998; Yamaguchi et al., 1999; Zhang et al., 1996b). The 
importance of protein-protein interaction for C/EBP mediated functions is 
underlined by the finding that C/EBP interacts with different protein partners in 
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the liver of young versus old mice  to execute its function (Iakova et al., 2003; 
Timchenko, 2003).
1.8 Max 
  Max is a basic region helix loop helix leucine zipper protein (Amati et al., 
1993; Amati et al., 1992; Amati and Land, 1994; Blackwood and Eisenman, 
1991).  Max belongs to Myc-Max-Mad network of proteins which has been 
shown to have critical role in regulating transcription. Max can form 
homodimers as well as heterodimers with Myc, Mad and several members of the 
Myc-Max-Mad family including Mnt and Mga.  These homodimers as well as 
heterodimers can bind specifically to E box DNA sequences with consensus 
CACGTG elements (Amati et al., 1993; Amati et al., 1992; Amati and Land, 
1994; Blackwood and Eisenman, 1991). 
  The Myc-Max-Mad network proposed by Eisenman postulates a central role of 
Max (Ayer et al., 1993). According to this model, Max forms transactivating 
complexes when associated with Myc but repressive complexes when bound to 
Mad proteins (Luscher, 2001). The binding of Myc-Max to promoters results in 
binding of the SW1/SNF complex which mediates chromatin remodeling. Also, 
Myc interacts with the TRAAP complex which has histone acetyl transferase 
activity.  So binding of Myc-Max to promoters results in chromatin remodeling 
and histone acetylation, which in turn, makes binding sites for transcription 
factors accessible, and results in transcriptional activation. Binding of the Mad-
Max complex to promoters results in the recruitment of the mSin3 repressor 
complex, which has histon deacetylase activity and chromatin compaction. This 
results in decreased accessibility of transcription factors to their binding sites 
and finally transcriptional repression. The shift in equilibrium from Myc-Max 
complexes to Mad-Max complexes results in shift from proliferation to 
differentiation (Luscher, 2001).  The model for transcriptional regulation by 
Myc-Max-Mad network of proteins is depicted in figure 9. 
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Figure 9. Transcriptional regulation by Myc-Max-Mad network of proteins (Luscher B, 
Gene, 2001) 
                            
  Studies of a Max knock-out mouse model show that Max is essential during 
growth and development (Shen-Li et al., 2000). Max -/- mice die  at days E5.5 to 
6.5. Switching from Myc-Max to Mad-Max heterocomplexes accompanies 
monocyte/macrophage differentiation (Ayer and Eisenman, 1993). One 
important study which suggests Max could have profound significance in 
granulopoiesis is that a mouse line that carries transgene encoding Max, exhibits 
a 50 to 60 fold elevation of blood neutrophils (Metcalf et al., 1995). 
Overexpression of Max has been shown to attenuate Myc-induced 
lymphoproliferation and lymphomagenesis in transgenic mice. (Lindeman et al., 
1995). This finding is very interesting since it is reported that downregulation of 
c-Myc by C/EBP is critical for granulopoiesis (Johansen et al., 2001)  and c-
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Myc is found to inhibit C/EBP dependent gene activation (Mink et al., 1996).
These findings suggest that Max can have important functions in granulopoiesis. 
  It has become increasingly clear that like most proteins, C/EBP might not 
work alone, but in association with other factors regulates gene transcription. 
However, studies involving protein–protein interactions of C/EBP at the global 
proteomic level are lacking. We therefore took advantage of high-throughput 
proteomics by mass spectrometry (LC-MS/MS) to identify proteins that 
specifically associate with C/EBP in vivo. In our screen, Max was identified as 
a novel interacting partner of C/EBP in addition to other new and known 
partners of C/EBP. Our data reveal Max as a novel co-activator of C/EBP, 
thereby suggesting a possible link between C/EBP and the Myc–Max–Mad 
network. 
1.9 The Peptidyl-prolyl cis/trans isomerase, PIN1  
  Phosphorylation of proteins at serine or threonine has been shown to play an 
essential role in signal transduction and cell cycle progression. It has been 
shown recently that phosphorylation of proteins on serine or threonine residues 
that immediately precede a proline (pSer/Thr-Pro), known as Pro-directed 
phosphorylation, is a central signaling mechanism controlling normal cell 
proliferation and malignant transformation (Blume-Jensen and Hunter, 2001; Lu 
et al., 2002). Interestingly, many oncogenes as well as tumor suppressors are 
strictly regulated by Pro-directed phosphorylation. The identification and 
characterization of the peptidyl-prolyl cis/trans isomerase, PIN1, which 
regulates the conformation of specific Pro-directed phosphorylation sites in 
certain proteins, has led to the discovery of a new post phosphorylation 
regulatory mechanism (Lu et al., 1996; Ranganathan et al., 1997; Yaffe et al., 
1997). 
     PIN1 belongs to the evolutionarily conserved peptidyl-prolyl isomerase 
(PPIase) family of proteins (Lu, 2003). PIN1 contains two functional domains- 
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an amino-terminal WW domain and a carboxy-terminal PPIase domain (Lu et 
al., 1999). The WW domain of PIN1 binds only to specific pSer/Thr-Pro motifs 
via protein-protein interaction and the PPIase domain catalyses a cis-trans
isomerization of the pSer/Thr-Pro motifs.  
             
Figure 10. Model for phosphorylation specific prolyl isomerization (Lu KP et al, Trends 
in Cell Biology, 2002) 
1.9.1 PIN1 as a molecular timer  
   PIN1 was originally discovered as a cell cycle protein essential for the 
regulation of mitosis (Lu et al., 1996). Later studies showed that overexpression 
of PIN1  prevents entry into mitosis (Shen et al., 1998). Pin1 depletion results in 
tumor cell survival and entry into mitosis. (Rippmann et al., 2000). Studies from 
Pin1-/- mouse embryo fibroblast cells display slower asynchronus growth than 
wild type cells (Fujimori et al., 1999). Pin1- null mice  had a marked increase in 
cell cycle duration in the primordial germ cells due to prolonged G1-S transition 
(Atchison et al., 2003). Also, Pin1 has been shown to be positively regulated by 
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E2F and PIN1 expression is increased as cells progress from G0 to S phase of 
the cell cycle (Ryo et al., 2002).  Collectively, all these data suggest that PIN1 
can have an important role in different phases of cell cycle  by functioning as a 
molecular timer (Yeh and Means, 2007).
1.9.2 Targets of PIN1 
  Recent works show that PIN1 mediated conformational changes following 
phosphorylation can have profound effects on catalytic activity, phosphorylation 
status, protein-protein interaction, subcellular localization, and/or protein 
stability of its substrates (Lu, 2003; Lu et al., 1999; Yeh and Means, 2007).  
PIN1 regulates the stability of many proteins including p53, Cyclin D1, ß-
catenin etc.  PIN1 increases the protein half life of p53 by inhibiting its binding 
to the Mdm2 ubiquitin  ligase, which  regulates the degradation of p53 (Wulf et 
al., 2002).  PIN1 binds and isomerizes cyclin D1 and thereby prevents its 
nuclear export and ubiquitin-mediated degradation, resulting in cyclin D1 
stabilization (Liou et al., 2002). 
   PIN1 has been shown to control cell cycle progression through regulating 
some key proteins such as c-Myc, c-Jun, Fos, Cyclin E and Cyclin D1. PIN1 
binds to c-Myc which is phosphorylated on Ser62 and Thr58. The binding of 
PIN1 has been shown to be necessary for the ubiquitination and degradation of 
c-Myc. Depletion of PIN1 results in stabilization of c-Myc (Yeh et al., 2004).  
Another important function PIN1 has is to regulate RNA polymerase II. PIN1 
increases C-terminal domain (CTD) phosphorylation of human RNA 
polymerase II by inhibiting the CTD phosphatase FCP1 and stimulating CTD 
phosphorylation by cdc2 / cyclin B (Xu et al., 2003).  It was shown that PIN1 
binds to c-Jun and increases the transcriptional activity of c-Jun in breast cancer 
development (Wulf et al., 2001). Some of the targets of PIN1 are depicted in 
figure 11.     
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Figure 11. Functional targets of PIN1 (Yeh ES and Means AR, Nature Reviews Cancer, 
2007) 
1.9.3 PIN1 and tumorigenesis  
         A role of PIN1 in tumorigenesis is suggested by the fact that it is  
overexpressed in many cancers including prostate, lung, ovary, cervical, breast, 
brain and skin (Bao et al., 2004; Wulf et al., 2001). Initial reports show that Pin1 
knock-out mice develop normally (Fujimori et al., 1999). Even though the Pin1
null animals display age dependent defects such as retinal atrophy, decreased 
body weight and testicular atrophy, no other phenotypic characteristics related to 
cancer were detected (Liou et al., 2002). Mice lacking Pin1 are resistant to 
tumorigenesis induced by oncogenic Neu or Ras (Wulf et al., 2004).  Inhibition 
of PIN1 in cancer cells via multiple approaches triggers apoptosis or suppresses 
the transformed phenotype (Lu et al., 1996; Rippmann et al., 2000). These 
studies show that PIN1 is essential for tumorigenesis. PIN1 is overexpressed in 
breast cancer and has been found to cooperate with Ras signaling in increasing 
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c-Jun transcriptional activity towards cyclin D1 (Wulf et al., 2001). 
Overexpression of cyclin D1 has been reported in many cancers (Hunter and 
Pines, 1994), including around 50% human breast tumors (Bartkova et al., 
1994).  These results indicate that PIN1 overexpression could be a prevalent  
event in human cancers (Lu, 2003). 
  It is suggested that PIN1 overexpression can function as a critical catalyst that 
amplifies multiple oncogenic signaling pathways during oncogenesis (Ryo et al., 
2003). Even though PIN1 is known to have important role in the development of 
many cancers, no data are published so far about any possible role of PIN1 in 
any type of leukemia. 
A recent study proposes that C/EBP  could be a PIN1 target (Miller, 2006). 
This study points out that S/T-P motifs in C/EBP could be regulated by PIN1 
mediated isomerization. PIN1 has been shown to be positively regulated by E2F 
and PIN1 expression is increased as cells progress from G0 to S phase of cell 
cycle (Ryo et al., 2002). It is important to note that C/EBP-p30 doesn’t repress 
E2F. E2F repression by C/EBP is required for granulopoiesis (Porse et al., 
2001). This demonstrates that lack of E2F repression by the C/EBP-p30 may 
leads to upregulation of PIN1. Rangatia et al has shown that  downregulation of 
the proto-oncogene c-Jun by C/EBP is critical for granulocytic lineage 
commitment (Rangatia et al., 2002). Overexpression of c-Jun blocks 
granulopoiesis and  c-Jun expression is high in AML patients with C/EBP
mutations (Rangatia et al., 2003). Moreover, PIN1 increases the transcriptional 
activity of c-Jun (Wulf et al., 2001) and PIN1 is upregulated in response to  c-
Jun overexpression (Rinehart-Kim et al., 2000). It is proposed that PIN1 can 
increase the stability of c-Jun (Wulf et al., 2005). Taken together, these studies 
suggest that PIN1 may have profound effects in AML patients in which C/EBP
is mutated. 
  In this study we show that C/EBP-p30 induces PIN1 mRNA levels and it is 
upregulated in   patients with acute myeloid leukemia. Inhibition of Pin1 leads to 
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myeloid differentiation suggesting that inhibition of Pin1 as a novel strategy in 
treating AML patients with C/EBP mutation.  
1.10 Aims of the study 
  Recent findings show protein-protein interactions coordinated by transcription 
factors have profound effect in hematopoiesis. Protein-protein interactions of 
C/EBP have been shown to be essential in granulopoiesis.  In the present study 
we aimed to identify the interacting proteins of C/EBP. Here we demonstrate 
the role of Max as an interacting partner of C/EBP and how this interaction is 
essential for the myeloid differentiation programme. These findings give new 
insights to the molecular mechanisms in granulopoiesis orchestrated by C/EBP.
  Experimental data from animal models as well as AML patient samples 
suggest that loss of function or expression of C/EBP is critical in AML 
development. C/EBP is mutated in around 9% of acute myeloid leukemia. The 
mutant form of C/EBP i.e., C/EBP-p30 exhibits dominant negative function 
over the wild type protein and blocks myeloid differentiation. The mechanism 
with which C/EBP-p30 mediates this differentiation block is poorly 
understood. An increasing number of studies suggest that the regulatory network 
around C/EBP-p30 could have a critical role in the development of AML. In 
the present study we also sought to demonstrate the role of PIN1 in AML with 
C/EBP mutation and how the regulatory network coordinated by PIN1 can 
have an important role in the dominant negative function of C/EBP-p30. These 
findings might lead to novel strategies for treating AML with C/EBP mutation.
38
2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals  
Acetonitrile      Sigma, Germany 
Acetic Acid      Merck, Germany 
Acrylamide-Bisacrylamide   Biorad, Germany 
Agar       Life Technologies, Scotland 
Agarose      Life Technologies, Scotland 
APS       Fluka, Switzerland 
Bromphenolblue     Sigma, Germany 
CHCA      Sigma, Germany
DAPI       Sigma, Germany
DTT       Sigma, Germany 
Dimethyl Sulfoxide    Sigma, Germany 
Dithioerythritol     Merck, Germany 
Deoxycholate     Merck, Germany 
-Estradiol      Sigma, Germany 
Ethanol      Merck, Germany 
Ethidium bromide     Sigma, Germany 
Ethylenediamine Tetra-Acetic Acid  Merck, Germany 
Formaldehyde      Sigma, Germany 
Formamide      Sigma, Germany 
Glycine      Sigma, Germany 
Glycerol      Merck, Germany 
Isopropanol      Merck, Germany 
Methanol      Merck, Germany 
PiB       Calbiochem, USA 
Puromycin      Sigma, Germany
Silver Nitrate     Merck, Germany 
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Sodium Carbonate     Merck, Germany 
Sodium Chloride     Sigma, Germany 
Sodium Thiosulfate    Merck, Germany 
Sodium Dodecyl Sulphate (SDS)  Sigma, Germany 
Trifluoroacetic Acid (TFA)   Merck, Germany 
Triton X-100     Sigma, Germany 
Trizol       Invitrogen, Germany 
Tween-20      Sigma, Germany 
Urea Plus      Merck, Germany 
2.1.2 Cell culture reagents 
Charcoal treated FBS    Hyclone, Germany 
DMEM      PAN, Germany 
Foetal bovine serum    GIBCO, Germany 
IMDM      Cambrex, United States 
Lymphocyte Separation Medium  PAA, Austria 
PBS       PAN, Germany 
Penicillin/Streptomycin    GIBCO, Germany 
RPMI 1640      PAA, Austria 
RPMI 1640       ATCC, Germany 
Trypsin EDTA     GIBCO, Germany 
2.1.3 Cell lines, AML blast cells, Primary Cells 
293T cells (human embyronic kidney fibroblast cells) 
U937 (human myeloid cell line, monoblastic) 
K562-C/EBP-p42-ER and K562-C/EBP-p30-ER (Erythroleukemic cells 
K562 cells stably transfected with C/EBP-p42-ER and C/EBP-p30-ER 
resepectively) (D'Alo et al., 2003). 
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Kasumi-6 (Myeloid leukemia cell line eastablished from the bone marrow cells 
of a patient with C/EBP mutation (Asou et al., 2003).
Blast cells from different AML patients were kind gift from the laboratory for 
leukemia diagnostic, Med III, Klinikum Großhadern, University of Munich, 
Germany. 
Human cord blood samples were collected after full term delivery with informed 
consent of the mothers from Klinikum Kröllwitz, Halle, Germany. 
Hematopoietic CD34+ cells were isolated from cord blood samples using 
CD34+ selection kit (Miltenyi Biotech, Germany). 
2.1.4 Plasmids 
Max expression plasmid (kind gift from Dr. Dirk Eick) 
In vitro translatable Max (kind gift from Dr. Robert Eisenman) 
BR3/C/EBP (basic region mutant) and LZ/C/EBP (leucine zipper domain 
mutant) (kind gift from Dr. Alan Friedman)
Wild type C/EBP and mutant C/EBP (C/EBP-p30) (Pabst et al., 2001b) 
Reporter construct p(C/EBP)2TK having two consensus C/EBP binding sites 
PIN1 promoter luciferase construct  (Ryo et al., 2002) 
PIN1 pcDNA (Zacchi et al., 2002) 
E2F1 expression vector (Johansen et al., 2001) 
c-Jun expression vector (Rangatia et al., 2002) 
2.1.5 shRNA / siRNA  
Max shRNA          Cat. No. RHS1764-9690535; Open Biosystems, Germany 
Control shRNA     Cat. No. RHS1707; Open Biosystems, Germany 
PIN1 siRNA          Cat. No. SI02662128; Qiagen, Germany 
Control siRNA      Cat. No 10277280; Qiagen, Germany
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2.1.6 Antibody 
Anti-C/EBP    Cat. No.  sc-61, sc-9315,  Santa Cruz Biotechnology, Germany 
Anti-Max          Cat. No.  sc-765, Santa Cruz Biotechnology, Germany 
Anti-c-Myc       Cat. No. sc-42, Santa Cruz Biotechnology, Germany 
Anti-PIN1          Cat. No. sc-15340, Santa Cruz Biotechnology, Germany 
Anti--Tubulin  Cat. No. sc-9104, Santa Cruz Biotechnology, Germany 
CD15                 Cat. No. 555401, BD Pharmingen, Germany 
CD11b               Cat. No. 555388, BD Pharmingen, Germany  
Anti-HA            Cat. No. 1867423, Roche Applied Science, Germany 
2.1.7 Reagent Kits 
Biorad-protein estimation kit                         Biorad, Germany 
CD34+ selection kit                                        Miltenyi Biotech, Germany 
Dual Luciferase assay kit                               Promega,  Germany 
ECL detection kit                                           Amersham Biosciences, Germany 
ImProm-II Reverse Transcription system      Promega, Germany 
LipofectAMINE plus                                     Invitrogen, Germany 
Nucleofector kit                                             AMAXA, Cologne, Germany 
Plasmid DNA Isolation kit                            Qiagen, Germany 
SYBR Green kit                                             Qiagen, Germany 
TNT-Reticulocyte lysate system                    Promega, Germany 
TRizol reagent                                                Invitrogen, Germany 
2.1.8 Mass Spectrometry: 
Reflex III MALDI-TOF                                 Bruker Daltonics, Germany 
AB4700 MALDI-TOF/TOF                          Applied Biosystems, Germany 
Nano LC                                                        LC Packing, Dionex, United States 
Mascot database search software                  Matrix Science 
AnchorChip plate                                          Bruker Daltonics, Germany 
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2.1.9 Miscellaneous  
ECL hyperfilm                               Amersham Biosciences, Germany 
Immobiline dry strip (pH 3-10)     Amersham Biosciences, Germany 
Protein agarose beads                    Roche Molecular Diagnostics, Germany 
Phosphatase inhibitor Cocktail      Sigma, Germany 
Protease inhibitors                         Sigma, Germany 
PVDF membrane                           Schleicher and  Schüll, Germany 
RNA quiashredder columns          Quiagen, Germany 
2.2 Methods 
2.2.1 Cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% heat 
inactivated foetal bovine serum and 1% Penicillin-Streptomycin; human 
embryonic kidney 293T cells were maintained in Dulbecco´s modified Eagle 
medium supplemented with 10% foetal bovine serum, 1% glutamine and 1% 
Penicillin-Streptomycin; K562-C/EBP-p42-ER and K562-C/EBP-p30-ER 
cells were maintained in RPMI 1640 without phenol red supplemented with 
10% charcoal treated foetal bovine serum, 1% Penicillin-Streptomycin and 2 
g/ml Puromycin; Kasumi-6 cells were cultured in RPMI 1640 supplemented 
with 20% foetal bovine serum, 1% Penicillin-Streptomycin and 2 ng/ml GM-
CSF; human CD34+ cells were cultured in Iscove’s modified Dulbecco’s 
medium with 20% heat-inactivated fetal calf serum, 100 ng/ml Flt3-ligand, 100 
ng/ml of stem cell factor, 100 ng/ml thrombopoietin, 100 ng/ml of interleukin-6 
(IL-6), 50 ng/ml of interleukin-3 (IL-3) and 100 U/ml  penicillin/streptomycin. 
2.2.2 Transfection 
2.2.2.1 Transient transfection by LipofectAMINE 
The day before transfection, 293T cells were trypsinized, counted and plated so 
that they were 50-80% confluent the day of transfection. Antibiotics were 
avoided during plating to help cell growth and increased transfection efficiency. 
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DNA was diluted in serum free medium and precomplexed with PLUS reagent 
(Invitorgen, Germany). The complete mixture was incubated at room 
temperature for 15 min. LipofectAMINE reagent was diluted and mixed in a 
serum free medium in a second tube. Pre-complexed DNA and diluted 
LipofectAMINE reagent (Invitorgen, Germany) were mixed and incubated for 
15 min at room temperature. During this incubation period, cells were rinsed 
with serum free medium to enable higher transfection activity. DNA-PLUS 
LipofectAMINE reagent complexes were added to each well containing fresh 
medium. The complexes were gently mixed with the medium; incubated at 37C 
at 5% CO2 for 3 hrs. After 3 hrs of incubation medium volume was increased to 
normal volume by adding medium containing 20% fetal bovine serum.  
2.2.2.1 Transient transfection by AMAXA 
 The Nucleofector kit (AMAXA, Cologne, Germany) was used essentially as 
described by the manufacturer.  2 g portion of plasmid DNA constructs were 
used for each transfection and the transfection efficiency was analyzed using a 
plasmid with eGFP marker. CD34+ cells, U937 and Kasumi-6 cells were 
transfected with nucleofection programmes U-08, V-01 and T-03, respectively.
2.2.3 Immunoprecipitation 
The immunoprecipitation (IP) was performed from 500–1000 g nuclear 
extracts  of U937 cells, 50 l slurry of protein A agarose beads and 2 g of 
respective antibodies and the corresponding IgGs as controls in an IP buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.25% sodium deoxycholate). 
Immunoprecipitated proteins were heated at 56°C for 30 minutes in 2X SDS 
loading buffer and then boiled at 95°C for 5 minutes. Denatured proteins were 
subsequently separated on 8% SDS PAGE and immunoblotted against 
respective antibodies. 
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2.2.4 Western blotting 
For Western blotting, 50 g total protein was denatured in the SDS sample 
loading buffer, separated on 8-10% SDS-polyacrylamide gels and transferred to 
an immobilon-P membrane (Millipore, USA). The membrane was incubated 
with respective primary antibody overnight and with horseradish peroxidase 
conjugated secondary antibodies for one hour. Signals were detected with the 
ECL Western blotting detection reagents. In all immunoblotting experiments a 
1:1000 dilution for primary and 1:2000 dilutions for secondary antibody was 
used. 
2.2.5 Proteomics 
  Nuclear extracts of U937 cells were used for immunoprecipitation with 
C/EBP antibody using protein A Agarose beads. After immunoprecipitation, 
beads with their associated proteins were lysed in urea lysis buffer for 1hr at RT 
on a rotating shaker. Lysed beads were passed through RNA quiashredder 
columns, and resulting supernatant containing dissolved proteins was 
ultracentrifuged for 50 minutes at 50,000 rpm at 22°C. In the first dimension, 
350 l of dissolved proteins after ultracentrifugation were separated on an 
immobiline dry strip pH 3-10 by isoelectric focussing (IEF) where proteins are 
separated on the basis of their isoelectric point (pI). The reduction and alkylation 
of separated proteins was carried out in urea buffer containing 2% DTE and 
2.5% iodoacetamide, respectively. Proteins were then separated in the second 
dimension using 12% SDS PAGE on the basis of their size (relative molecular 
weight). 2D gels were silver stained to visualise the protein spots.
  The protein spots were excised from gels, destained, and in gel digestion was 
performed with 200 ng trypsin in ammonium bicarbonate solution for 16 hours. 
The digested peptides were eluted in 70% acetonitrile, lyophilised and 
resuspended in 5 l of 0.1% TFA in 10% acetonitrile. The dissolved peptides 
were mixed in 1:1 ratio with DHB (2, 5-dihydroxybenzoic acid) matrix solution 
and loaded on an anchorChip target plate (Bruker Daltonics, Germany). Peptide 
45
mass fingerprint (PMF) was generated by Matrix Assisted Laser Deionization-
Time of Flight (MALDI TOF; REFLEX III, Bruker Daltonics) mass 
spectrometry and corresponding proteins were identified by MASCOT database 
searches. 
  For LC-MS/MS analysis of interacting proteins of C/EBP, the beads after 
immunoprecipitation were denatured with SDS sample loading buffer, separated 
on 10% SDS-polyacrylamide gel and silver stained. The individual bands were 
excised and processed for trypsin digestion. The digested protein samples were 
fractionated by Nano LC (LC Packing, Dionex) using 500 µm i.d. x 5mm, C18 
reverse phase column with a flow rate of 200 nl/min and loaded on an 4700 
sample plate. Peptide mass fingerprint (PMF) was generated by Matrix Assisted 
Laser Deionization-Time of Flight (MALDI TOF/TOF, Applied Biosystem) 
mass spectrometry and corresponding proteins were identified by MASCOT 
database searches. 
2.2.6 Immunofluorescence 
U937 cells (3 X 105), under uninduced condition or induced with RA, were 
cytocentrifuged on glass slides with coverslips, fixed using 1:1 
methanol/acetone and permeabilized using 0.3% Triton X. After blocking in 
PBG (0.5% BSA, 0.045% Fish–gelatin in phosphate-buffered saline) containing 
5% FBS, the fixed cells were incubated with anti-C/EBPa, anti-Max and anti-
Myc antibodies, followed by incubation with corresponding Alexa Fluor 488 
chicken anti-goat, Alexa Fluor 594 chicken anti-rabbit and anti-mouse IgG 
secondary antibodies (Molecular Probes) and DAPI (1 mg/ml) for 15 min. The 
cells were mounted in aqueous mounting medium and the images were acquired 
and analyzed using Leica fluorescence microscope (X100, X60). 
2.2.7 Promoter assay 
293T cells were transiently transfected using LipofectAMINE (Invitorgen, 
Germany) as described by the manufacturer. Firefly luciferase activities from 
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the constructs pTK, p(C/EBP)2TK and Renilla luciferase activity from the 
internal control plasmid pRL-null were determined 24 h after transfection using 
the Dual-Luciferase Reporter Assay System (Promega,  Germany). Firefly 
luciferase activities were normalized to the Renilla luciferase values of pRL-
null. Results are given as means and standard errors of the means of three 
independent experiments. The following DNA concentrations of the reporter 
constructs and expression plasmids were used for LipofectAMINE Plus 
transfections: 0.1 g of pCDNA3-human C/EBP (wild type), 0.1 g of 
C/EBP-p30, 0.1 g of Max, 0.1 g of pTK, 0.1 g of pCDNA3 PIN1, 0.1 g of 
c-Jun, 0.05 g of E2F1, 0.1 g of p(C/EBP) 2TK and 0.01 g of the internal 
control plasmid pRL-null. 
2.2.8 FACS analysis 
For flow cytometry analysis, 106cells were washed twice with PBS and 
resuspended in 50 l of PBS with 2 l of the respective antibody. Incubation 
was performed for 20 minutes in ice. After the incubation, cells were washed 
with PBS, resuspended in PBS and analyzed by flow cytometry in FACScan
(Becton Dickinson). 
2.2.9 Chromatin immunoprecipitation assay 
Crosslinking of proteins to DNA was done by the direct addition of 
formaldehyde (final concentration 1% (v/v) to cultured cells for 10 min at 370C. 
Glycine was added to a final concentration of 0.125M to stop cross-linking. 
Fixed cells were pelleted by centrifugation and equentially washed and 
sonicated (five times for 20 s each) to make soluble chromatin. Samples of total 
chromatin were taken at this point to use as a positive control in the PCRs (input 
chromatin). Antibodies against C/EBPa, Max and c-Myc were used overnight at 
40C. After serial elution, washing and reverse cross linking, the samples were 
extracted twice with phenol/chloroform and precipitated with ethanol overnight 
in the presence of 20 mg glycogen as a carrier. DNA fragments were recovered 
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by centrifugation, resuspended in distilled water, and used for PCR 
amplification. For detection of immunoprecipitated C/EBP promoter region, 
two primers, forward 5´-CCGCTACCGACCACGTGGGCG-3´(which 
corresponds to -280 to -260 bases) and reverse 5´-
GCACCTCCGGGTCGCGAATGG-3´(which corresponds to -2 to +19 bases), 
were used for Q-RT-PCR amplification. The amplified product (299 bases) 
encompasses the CACGTG site in the C/EBP promoter.  
2.2.10 mRNA expression analysis 
Total RNA was isolated from leukemic patient samples, processed and analyzed 
on the Affymetrix HG-U133A and HG-U133B chips as described before 
(Schoch et al., 2002). The data from Affymetrix analysis were normalised 
together according to the procedure described before (Huber et al., 2002). 
Normalized expression data were then analyzed with the R software package 
and the “boxplot” function (www.r-project.org). Expression signal intensities 
are expressed on a logarithmic scale.  
2.2.11 Quantitative Real-Time PCR 
Total RNA was isolated from cells with Trizol reagent (Invitorgen, Germany).  
750 g of RNA was used to synthesize cDNA by Reverse Transcription.  Equal 
amounts of cDNA were taken for a subsequent quantitative real-time PCR (Q-
RT-PCR) using the SYBR Green PCR kit (Qiagen, Germany) in a Rotor-Gene 
RG-3000 (Corbett Research, Australia). The delta delta CT value (		CT) was 
then calculated from the given CT value by the formula 		CT = [CT (gene of 
interest)–CT (GAPDH)] Test – [CT (gene of interest)–CT (GAPDH)] Control. The 
fold change was calculated as fold  change = 2–		CT (Livak and Schmittgen, 
2001). 
The primers used in the analysis are shown in table 2:  
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Table 2. 
Gene Acc. No.     Sequence Amplicon 
(bp) 
Position at 
the cDNA 
sequence 
PIN1 NM_006221 For. 5´AAG ATG GCG GAC GAG GAG 3´ 
Rev. 5´CAC TCA GTG CGG AGG ATG AT  3´
494 1-491 
c-Jun NM_002228 For.5´GCA TGA GGA AAC GCA TCG CTG 
CCT CCA AGT 3´ 
Rev. 5´GCG ACC AAG TCC TTC CCA CTC 
GTG CAC ACT 3´ 
400 776-1175 
G-CSFR BC053585 For. 5´AAG AGC CCC CTT ACC CAC TAC 
ACC ATC TT 3´ 
Rev. 5´TGC TGT GAG CTG GGT CTG GGA 
CAC TT 3´ 
340 1666-2005 
GAPDH NM_002046 For. 5´ACC ACA GTC CAT GCC ATC AC 3´ 
Rev. 5´TCC ACC ACC CTG TTG CTG TA 3´ 
452 526-977 
2.2.12 Ubiquitination Assay 
293T cells were transiently transfected with different constructs as described 
(Figure 27), 24 hours after transfection cells were lysed in RIPA buffer followed 
by c-Jun immunoprecipitation from 500g total protein.  The protein samples 
after immunoprecipitation were analysed in a 10% SDS-PAGE gel and probed 
for HA antibody.  
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3. Results 
3.1 Max as a novel co-activator of myeloid transcription factor 
C/EBP
3.1.1 Identification of Max, a heterodimeric partner of Myc, as a novel 
interacting protein of C/EBP
  To identify interacting proteins of C/EBP in vivo under physiological 
conditions on a cellular level, we applied proteomics technique coupled with 
mass spectrometry using the immunoprecipitation conditions of endogenous 
C/EBP from myeloid U937 cells as a model system. 
  Under our experimental conditions, we could specifically immunoprecipitate 
endogenous C/EBP from the nuclear extracts of U937 cells (Figure 12A) and 
co-immunoprecipitate other endogenous proteins (as positive controls) such as 
c-Jun (Figure 12B) which was not present in the isotype IgG control. 
Immunocomplexes were further processed for proteomic analysis. The protein 
spots excised from the 2D gels (Figure 12C, spots are numbered) were identified 
by MALDI-TOF MS. Additionally, the individual bands were excised from 
Coomassie/Silver-stained SDS-PAGE gels (Figure 12D) and processed for LC-
MS/MS. From both screens, we were able to identify 10 proteins by MS, which 
potentially interact with C/EBP (Table 3). Among these proteins, was Max. 
C/EBP was also identified by MS analysis of the corresponding band (Figure 
12D), thereby serving as a control for our experimental setup. The discovery of 
Max as a novel C/EBP partner is intriguing because of the role Max plays in 
switching from Myc-Max to Mad-Max heterocomplexes during myeloid 
differentiation (Ayer and Eisenman, 1993). We therefore selected Max for 
further functional and biological characterization.
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Figure 12. Mass spectrometry based proteomics identification of C/EBP interacting 
proteins. A) C/EBP IP from nuclear extracts of U937 cells and a corresponding 
immunoblotting (IB) with anti-C/EBP antibody to confirm the presence of C/EBP protein 
in the IP complex. In vitro-translated C/EBP (ivt, lane 1) was used as a positive control in 
the Western blot. B) C/EBP IP and corresponding IB with anti-c-Jun antibody to show 
endogenous proteins co-precipitated with C/EBP. In vitro translated c-Jun was used as a 
positive control for c-Jun. C) Silver-stained 2D gels showing proteins specifically interacting 
with C/EBP. C/EBP was immunoprecipitated from nuclear extracts using anti-C/EBP
antibody and the immunocomplex separated in the first dimension by pH 4–7 IPGphor strips 
followed by their separation in the second dimension using 12% SDS-PAGE. As a specificity 
control, we used immunoprecipitation with IgG under similar conditions. D) Silver-stained 
SDS-PAGE gels after IP with anti-C/EBP and anti-IgG. The bands were excised and peptide 
mixture after trypsin digestion was run on a reverse-phase liquid chromatography and the 
peptides identified by MALDI-TOF-TOF 
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Table 3. Mass spectrometry based identification of interacting proteins of 
C/EBP
Spot 
no. 
Acc.no. Protein name Mol.wt. 
  1 A42611 Max 21.029 
  2 Q9UP93 Macrophin1 fragment 620.00 
  3 M2OM_Hum Mitochondrial 2-oxoglutarate/malate carrier 
protein 
34.08 
  8 A47213 Beta fodrin 146.55 
 12 Q96QA8 RPGR interacting protein 1 147.33 
 13 Q9P1U9 ZNF45 80.44 
 15 FAHUAA Actinin 1 103.48 
 16 Q9UKD2 60 S ribosomal protein 127.60 
  * NMD3A N-methyl-D-aspartate receptor 3A 126.67 
  * SMADIP1 Smad interacting protein 1 137.84 
 * represents proteins identified by liquid chromatography coupled tandem mass spectrometry 
3.1.2 C/EBP and Max interact in a cellular setting: confirmation of 
proteomics data 
To confirm the observed interaction of Max with C/EBP, we performed 
reciprocal immunoprecipitation. Our results demonstrate that C/EBP interacts 
with Max and vice versa (Figure 13) in vivo, and thereby confirm the results 
from the interaction screen. It is important to note that for the same amounts of 
nuclear extracts used (5 and 10 mg) as input controls, the levels of the two 
transcription factors are dramatically different, which is likely due to Max being 
more stable than C/EBP. 
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Figure 13. Confirmation of C/EBP-MAX interaction. Reciprocal IPs: C/EBP   and Max 
were immunoprecipitated (IP C/EBP, IP Max) from nuclear extracts of U937 cells by 
incubation with anti-C/EBP   and anti-Max, respectively, and respective IgG as controls. The 
blot was first probed with anti-C/EBP   antibody, stripped and reprobed with anti-Max 
antibody. 
3.1.3 The BR3 domain of C/EBP is involved in its interaction with Max 
To investigate the protein domains that might be involved in the C/EBP–Max 
interaction, we performed co-immunoprecipitation studies using different 
mutants of C/EBP. The different C/EBP mutants used in this study were 
BR3/C/EBP (arginine 297, lysine 298, aginine 300 and lysine 302 in the basic 
region mutated), GZ/LZ (the leucine zipper of C/EBP is replaced with GCN4 
leucine zipper) and L1-2V (leucine 1 and 2 in the leucine zipper mutated to 
valine) (Liu et al., 2003). C/EBP and its various mutants were transiently 
transfected into 293T cells, and cotransfected with an expression plasmid for 
Max containing a carboxy-terminal HA tag. Max was then immunoprecipitated 
from nuclear extracts using Max antibody. The associated complexes were 
assayed by immunoblotting for C/EBP using C/EBP antibody. Our results 
demonstrate that C/EBP could be co-immunoprecipitated when IP was 
performed using Max antibody in samples in which wild-type C/EBP: wild-
type Max, GZ/LZ C/EBP: wild-type Max and L1-2V C/EBP: wild-type Max 
were co-expressed (Figure 15B, lanes 4, 3, 1, respectively). However, C/EBP
could not be co-immunoprecipitated in immunoprecipitated samples in which 
basic region mutant BR3-C/EBP: wild-type Max was co-expressed (Figure 
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14B, lane 2). We also show that Max could be specifically immunoprecipitated 
(as controls) with immunoblot for Max using HA antibody (Figure 14B, lower 
panel). These data show that the basic region of C/EBP is involved in its 
interaction with Max in a cellular setting. 
  
Figure 14. Interaction of C/EBP with Max involves the DNA-binding domain of 
C/EBP: A) The basic region of C/EBP is involved in its interaction with Max. Schematic 
representation of wild-type hC/EBP and different mutants used in this study. TAD, 
transactivation domains 1 and 2; BR, basic region; LZ, leucine zipper domain; HLH, helix–
loop–helix. B) hC/EBP  wild type and its mutants were transfected in 293T cells and co-
transfected with wild-type Max expression plasmid. At 24 h post-transfection, the nuclear 
extracts were prepared and IP of Max performed for the samples followed by immunoblot for 
C/EBP   or Max using anti-C/EBP   and HA antibodies, respectively. 
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3.1.4 C/EBP–Max but not Myc–Max colocalize during granulocytic 
differentiation of myeloid U937 cells 
  Given the fact that C/EBP and Max are nuclear transcription factors and the 
observation that they interact in vivo, we next investigated the localization of 
these proteins by indirect immunofluorescence in myeloid U937 cells. We 
observed both endogenous C/EBP  and Max to be localized in intranuclear 
structures (Figure 15A) and the overlay of the two images shows that both 
proteins colocalize in these intranuclear structures (Figure 15A, panel 4; yellow 
signal). 
  We next investigated the effect on C/EBP–Max colocalization when the cells 
were triggered for granulocytic differentiation by RA for 24 hr. We observed 
intranuclear staining with C/EBP and Max antibodies, and the overlay of the 
two images shows that both proteins remain colocalized even after RA treatment 
of the cells (Figure 15B, panel 4; yellow signal). As Max is associated with 
Myc, we also analyzed their localization in U937 cells. We observed that 
endogenous Myc–Max colocalize in the nucleus under uninduced condition 
(Figure 15A, lower panels). On the other hand, no intranuclear c-Myc signal 
could be detected after RA treatment (Figure 15C, lower right panel 4; only 
green signal from Max). We next investigated the expression of c-Myc, Max and 
C/EBP before and after RA treatment from various fractions (nuclear fraction 
(NF) and cytoplasmic fraction (CF) by Western blotting, using specific 
antibodies (Figure 16D). Our results revealed that the c-Myc protein level was 
drastically decreased in both fractions (Figure 15D) by RA. However, C/EBP
was undetectable in the CF and slightly increased in the NF by RA when 
analyzed by immunoblotting. Max, on the other hand, was relatively unchanged 
under induced and uninduced conditions. These data suggest that 
retention/colocalization of C/EBP–Max, and not Myc–Max heterocomplexes, 
in the nucleus might be important events during granulocytic differentiation of 
U937 cells. 
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Figure 15. Endogenous C/EBP-Max but not Myc–Max remains colocalized during 
granulocytic differentiation of U937 cells. A) Indirect immunofluorescence staining for 
C/EBP   (anti-goat; Santa Cruz), Max (anti-rabbit; Santa Cruz) and Myc (anti-mouse, Santa 
Cruz) using respective conjugated secondary antibodies (Molecular Probes). Indirect 
immunofluorescence staining for B) C/EBP-Max and C) Myc–Max using conjugated 
antibodies (Molecular Pobes) in U937 cells after RA treatment. D) Immunoblot analysis 
showing expression of c-Myc, Max and C/EBP   under RA-induced and uninduced 
conditions from nuclear and cytoplasmic fractions. Blots were stripped and reprobed with 
specific antibody.  NF: nuclear fraction; CF: cytoplasmic fraction. 
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3.1.5 Max enhances the ability of C/EBP to transactivate a minimal 
thymidine kinase promoter 
       To investigate the functional importance of the C/EBP –Max interaction 
and the colocalization of these proteins, we performed transient transfection 
assays in the human embryonal kidney cell line 293T and the myeloid cell line 
U937 using as a reporter a minimal TK promoter containing two CCAAT 
binding sites cloned upstream of the luciferase reporter gene. Transfection of a 
Max expression construct significantly enhanced the ability of C/EBP to 
transactivate a minimal TK promoter containing two CCAAT binding site in a 
dose dependent manner (Figure 16A). In control experiments, no effect of Max 
on C/EBP activity was observed when promoter with no CCAAT binding sites 
was used. Similar results were obtained with myeloid U937 cells (Figure 16B). 
Interestingly, co-transfection studies with the human 2200 bp C/EBP promoter  
construct having bases -1 to -2200 with respect to the transcription start site 
(which has an intact E-box site and no CCAAT site) revealed that C/EBP alone 
was unable to transactivate the promoter, whereas, co-transfection of Max led to 
a weak but significant increase in the promoter activity (Figure 16C). It is 
important to point out that Max itself does show some activation.  
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Figure 16. Max enhances the transactivation capacity of C/EBP in transient 
transfection assays. A, B) Transient transfection in 293T and U937 cells with a reporter 
construct of a minimal TK promoter with CEBP binding sites only p(CEBP)2TK and 
expression plasmids for hC/EBP   and Max. pTK (without CEBP sites) was used as control. 
Luciferase activities were measured 24 h after transfection and the values normalized by using 
Renilla luciferase PRL0. C) Transient transfection in 293T cells with a 2200 bp hC/EBP   
promoter showing increased promoter activation when Max is coexpressed. 
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3.1.6 C/EBP and Max associate in vivo: a Myc–Max–Mad link 
  To further elucidate the mechanism by which Max augments the transcriptional 
activity of C/EBP, we hypothesized that Max might associate with the 
hC/EBP promoter in vivo because similar to C/EBP, Max also possesses a 
DNA binding basic region. To test this possibility, we performed quantitative 
radioactive and non-radioactive chromatin immunoprecipitation (ChIP) in U937 
cells (Figure 17). Chromatin was subjected to IP by using antibodies directed 
against C/EBP, c-Myc and Max. The presence of Max in the C/EBP promoter 
was detected by amplifying a promoter region using primers specific for a 280 
bp region of the C/EBP promoter that encompasses the CACGTG site 
(commonly referred to as E-box; Figure 17A). The E-box is conserved in the 
human and mouse C/EBP promoter (Figure 17A). We observed that under 
normal physiological conditions (uninduced), endogenous c-Myc and Max were 
present on the C/EBP promoter and there was undetectable endogenous 
C/EBP occupancy on the hC/EBP promoter (Figure 17B). IP using an 
isotype-matched IgG served as a negative control. 
We next investigated the effect on heterocomplex formation of Max and 
C/EBP at the hC/EBP promoter upon differentiation by RA. We observed that 
both Max and C/EBP appeared on C/EBP promoter and in fact, more C/EBP
was associated with the promoter in the context of chromatin upon 
differentiation induction (Figure 17C, lane 4). The amount of Max bound to the 
promoter was fairly constant. DNA recovery was quantified as a percentage of 
the total input chromatin (lanes 5–7). A promoter without the CACGTG site, 
such as GAPDH promoter (Figure 17D), was used as a negative control for 
C/EBP and Max occupancy and hTERT promoter (Figure 17E) as a positive 
control for Myc and Max interaction on the CACGTG site (E-box). Thus, 
C/EBP and Max associate in vivo in the context of chromatin and are 
associated together more strongly on the hC/EBP promoter when the cells are 
induced towards granulocytic differentiation.  
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Figure 17. Max is associated at the hC/EBP   promoter in vivo and Max–C/EBP  
associate strongly during granulocytic differentiation. ChIP assay was performed with 
untreated and RA-treated U937 cells, and the precipitated chromatin was PCR-amplified 
using specific primers.A) Comparison of the human and mouse C/EBP promoters 
encompassing a consensus CACGTG sequence, commonly referred to as E-box and known to 
be occupied by Myc-Max heterodimers. B) In vivo occupancy by Myc and Max at the 
hC/EBP   promoter in logarithmically growing and C) by Max-C/EBP   in RA treated U937 
cells. D, E) ChIP assay using GAPDH promoter (negative control) and human TERT 
promoter (positive control with a non-radioactive RT-PCR. 
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3.1.7 Overexpression of Max and C/EBP promotes differentiation along 
the granulocytic pathway in human hematopoietic CD34+ cells 
 We next asked whether the interaction of Max with C/EBP is biologically 
important for C/EBP functions. For this, we performed overexpression studies 
using human hematopoietic CD34+ cells. Our results revealed that 
overexpression of Max or C/EBP  alone in CD34+ cells leads to a significant 
increase in the proportion of CD11b+ (Figure 18, upper panel) and CD15+ 
(Figure 18, lower panel) cells compared to the mock-transfected control, 
respectively.  
Figure 18. Overexpression of Max induces gramulocyte differentiation.  The expression 
plasmids for human C/EBP   and Max were transfected into human hematopoietic CD34+ 
cells by using AMAXA. The surface expression of CD11b and CD15 was analyzed by flow 
cytometry at day 4. The histograms represent data from three different experiments.  
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3.1.8 Stable silencing of Max by short hairpin RNA reduces the 
differentiation-inducing capacity of C/EBP in human hematopoietic 
CD34+ cells 
 If Max is a biologically important co-activator of C/EBP, silencing of Max 
should inhibit differentiation induction by C/EBP. To address this, we 
performed RNA interference experiments in human hematopoietic CD34+ cells 
by using short hairpin RNA (shRNA) against Max and control shRNA. Cells 
were transfected with expression plasmids for C/EBP alone and/or co-
expressed with shRNA against Max, control shRNA, and the cells cultured in 
media containing puromycine for two days. After selection, the cells were 
analyzed for granulocytic differentiation, using CD15 expression as a marker. 
Our results revealed that C/EBP alone induces granulocytic differentiation 
(CD15+) as compared with the mock-transfected CD34+ (Figure 19A). 
Coexpression of Max shRNA led to a significant decrease in CD15+ population 
(about two fold), whereas control shRNA did not lead to any significant 
reduction in CD15+ population (Figure 19A, compare histograms). The 
reduction of Max protein level with shRNA was confirmed by Western blotting 
and Max shRNA did not affect the expression of C/EBP (Figure 19B). Thus, 
Max is important for C/EBP-mediated effects on granulocytic differentiation 
and might have an important role in stem cell development. 
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Figure 19. Stable silencing of Max by shRNA inhibits C/EBP  induced differentiation in 
human hematopoietic CD34+ cells. A) The expression plasmid for human C/EBP   and/or 
expression Arrest shRNA Max plasmid (Open Biosystems, Cat. No. RHS1764-9690535) 
were transfected into human hematopoietic CD34+ cells by AMAXA transfection method. 
After their selection in puromycine, the cells were analyzed for the surface expression of 
CD15 by flow cytometry. Control shRNA was also used in all the experiments and is shown. 
The histograms represent the data from three different experiments. B) A Western blot for 
Max using anti-Max antibody showing silencing of Max at the protein level by ShRNA 
MAX. The blot was stripped and reprobed with C/EBP   antibody. 
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3.2 The critical role of PIN1 upregulation in Acute Myeloid 
Leukemia with C/EBP mutation 
3.2.1 C/EBP-p30 induces PIN1 mRNA expression in myeloid cells 
It has been shown that mutant C/EBP (C/EBP-p30) blocks the wild type 
C/EBP in a dominant negative manner and has been shown to block the 
differentiation of myeloid precursor cells (Pabst et al., 2001b). Recent findings 
suggest that  C/EBP mediated E2F repression as critical step in myeloid 
differentiation programme and lack of this repression provides a platform on 
which AML like syndrome evolve (Schuster and Porse, 2006). Based on this, we 
asked how E2F target genes could have a role in the differentiation block 
observed in AML with C/EBP mutation. Growing number of studies support 
the oncogenic potential of PIN1, which is an E2F1 target gene. We investigated 
how C/EBP-p30 regulates PIN1 levels. We chose K562-ER cell lines (D'Alo et 
al., 2003) as well as Kasumi-6 cells (Asou et al., 2003) for the initial 
experiments. K562-ER cells are an early multipotential line derived from the 
K562 cell line, which was obtained from a patient with chronic myeloid
leukemia. Kasumi-6 is a myeloid leukemia cell line established from the bone 
marrow cells of an individual with acute myeloid leukemia, subtype M2 having 
C/EBP mutation and expressing both the p42 and p30 isoforms of the C/EBP
protein endogenously. We induced C/EBP-p30 by ß-Estradiol treatment in the 
K562-C/EBP-p30-ER cell line. We observed that C/EBP-p30 induces PIN1 
mRNA expression (Figure 20A). Next we overexpressed C/EBP-p30 by 
AMAXA transfection in Kasumi-6 cells. Similar results were obtained with 
myeloid Kasumi-6 cells also (Figure 20B).  
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A. B. 
Figure 20. C/EBP-p30 induces PIN1 mRNA expression. A) K562- C/EBP-p30-ER cells
were induced with ß Estradiol for respective time points to induce C/EBP-p30 and total 
RNA was isolated at respective time points, proceeded for reverse transcription followed by 
quantitative real time PCR for PIN1 B) Kasumi-6 cells were transfected with mock vector or 
C/EBP-p30 vector by AMAXA and isolated total RNA after 24 hr and proceeded for Real 
time PCR for PIN1. Values were normalized with GAPDH mRNA. The results are the means 
from three independent experiments, and error bars represent the standard errors of mean.   
3.2.2 PIN1 is upregulated in different AML subypes including AML with 
C/EBP mutations.  
  It is suggested that PIN1 overexpression can function as a critical catalyst that 
amplifies multiple oncogenic signaling pathways during oncogenesis (Ryo et al., 
2003). Recent studies show that PIN1 is overexpressed in many cancers 
including prostate, breast, lung, ovary and colon cancer (Bao et al., 2004). PIN1 
is transcriptionally regulated by E2F  (Ryo et al., 2002). Given the fact that 
C/EBP mediated E2F repression is a critical step in granulopoiesis (Porse et al., 
2001) and that C/EBP is inactivated by various mechanisms in AML including 
mutations of C/EBP itself, we hypothesized that PIN1 expression in AML 
patient samples could be high in comparison to normal control samples. mRNA 
expression analysis and Western blot analysis show that PIN1 mRNA and 
protein are upregulated in various AML subtypes including AML with C/EBP
mutation (Figure 21).  
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Figure 21. PIN1 mRNA and protein expression is high in different subtypes of leukemia. 
A) Affymetrix analysis was done with AML blast cells using total RNA isolated from 
leukemic patient samples, processed and analyzed on the Affymetrix HG-U133A and HG-
U133B chips. Expression signal intensities are expressed in logarithmic scale. B) Western 
blot analyis for Pin1 using lysates prepared from AML blast cells.  nBM: normal bone 
marrow, CML: chronic myeloid leukemia, AML NK: Normal karyotype, AML Comp (CK):  
Complex karyotype, AML M4: AML with the CBF/MYH11 fusion gene, AML M3: AML 
with PML/RARA fusion gene, AML M2: AML with AML1/ETO fusion gene, AML FLT3: 
AML with FLT3 activating mutation and CEBPA Mut :  AML with CEBPA mutation.
3.2.3 Silencing PIN1 overcomes the dominant negative action of the mutant 
C/EBP over the wild type protein in a promoter assay 
  To investigate the functional importance of PIN1 upregulation by C/EBP-p30 
and how this can be important for the dominant negative function of C/EBP-
p30, we performed reporter gene assays in 293T cells. Cells were transfected 
with a minimal TK promoter containing two CCAAT binding sites cloned 
upstream of the luciferase reporter gene (pTK CEBPA). Transfection of wild 
type C/EBP enhanced the promoter activity and C/EBP-p30 was able to block 
the promoter activity of the wild type protein (Figure 22). Transfection of PIN1 
siRNA (Cat. No. SI02662128; Qiagen, Germany) was shown to overcome the 
dominant negative effect of C/EBP-p30, while control siRNA (Cat. No 
10277280; Qiagen, Germany) didn’t make any effect. No effect was observed 
when cells were transfected with PIN1 siRNA / control siRNA alone. 
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Figure 22. Silencing of PIN1 overcomes the dominant negative action of C/EBP-p30 over the 
wild type protein in promoter assay. Transient transfection in 293T cells with a reporter construct 
having minimal TK promoter with CEBP binding sites and expression plasmids for C/EBPα−p42, 
C/EBPα−p30, PIN1 siRNA and control siRNA. Luciferase activities were measured 24 h after 
transfection and the values were normalized by using Renilla luciferase PRL0. The results are the 
means from three independent experiments, and error bars represent the standard errors of mean.  
3.2.4 PIN1 inhibition by PiB can overcome the differentiation block 
observed in human myeloid cells.  
To further understand how silencing of PIN1 activity is biologically significant 
in the context of C/EBP mutation, we carried out myeloid differentiation 
experiments in AML blast cells with C/EBP mutation and Kasumi-6 cells. For 
silencing PIN1, we used the  PIN1 inhibitor, PiB (Uchida et al., 2003). PiB has 
been shown to inhibit PIN1 activity by binding to the PPIase domain of PIN1. 
Myeloid cell differentiation was assessed by CD11b and CD15 expression by 
FACS analysis as well as G-CSFR expression by Real Time RT-PCR. As shown 
in figure 23, treatment of cells with PiB was able to induce the differentiation. 
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Figure 23. PIN1 inhibition using the PiB can overcome the differentiation block 
observed in human myeloid cells.  AML blast cells with C/EBP mutation and Kasumi-6 
cells were treated with PiB (5M) for 6 days and myeloid cell differentiation was assessed by 
FACS analysis using CD11b and CD15 expression as well G-CSFRexpression by Real Time 
RT-PCR analysis. The results are the means from three independent experiments, and error 
bars represent the standard errors of mean.   
 3.2.5 PIN1 inhibition can upregulate C/EBP-p42 protein level. 
C/EBP mutations are characterized by low C/EBP wild type protein level 
(Pabst et al., 2001b). We have shown that inhibition of PIN1 can induce 
differentiation in myeloid cells (Figure 23). We hypothesized that inhibition of 
PIN1 could upregulate the C/EBP wild type protein level. We induced Kasumi-
6 cells with PIN1 inhibitor, PiB for different time points followed by RIPA lysis 
and Western blot with C/EBP specific antibody. As shown in figure 24, 
C/EBP protein level increased during inhibition of PIN1.
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Figure 24. PIN1 inhibition by PiB can upregulate C/EBP-p42 protein level. Kasumi-6 
cells were treated PiB or ethanol for different time points. Cells were lysed and subjected to 
Western blot analysis using C/EBP antibody. Values below the gel image indicate the 
upregulation (fold) of C/EBP wild type protein level normalised to ß-Tubulin. 
3.2.6 C/EBP-p30 induces PIN1 promoter activity in association with E2F1 
and C/EBP-p42 interferes with the transactivation of the PIN1 promoter 
  Since we could observe C/EBP-p30 induces PIN1 expression, we next 
investigated how C/EBP proteins regulate PIN1 mRNA level.  PIN1 is 
transcriptionally regulated by E2F (Ryo et al., 2002). E2F repression by C/EBP
is necessary for granulopoiesis and  loss of E2F inhibition by C/EBP  has been 
shown to be sufficient to initiate AML like transformation of the granulocytic 
lineage (Porse et al., 2005). C/EBP-p30 lacks the domain necessary for E2F 
inhibition.  We hypothesized that in the presence of C/EBP-p30, E2F is able to 
transactivate PIN1 promoter activity and/or C/EBP-p30 can increase the 
transactivation in cooperation with E2F. We performed luciferase promoter 
assay for PIN1 promoter (Ryo et al., 2002) with E2F, C/EBP-p30 and C/EBP-
-Tubulin 
PiB treatment 
(Days) 
0 1 3 5 7 
C/EBP-p42 
C/EBP-p30 30 kD 
75 kD 
50 kD 
50 kD 
25 kD 
35 kD 
1.7 1.0 1.5 1.9 1.9 C/EBP-p42 / -Tubulin 
-Tubulin 
Ethanol control 
(Days) 
0 1 3 5 7 
C/EBP-p42 
C/EBP-p30 30 kD 
75 kD 
50 kD 
50 kD 
25 kD 
35 kD 
0.6 1.0 0.4 1.1 0.9 C/EBP-p42 / -Tubulin 
69
p42. We observed that C/EBP-p30 could increase the transactivation of PIN1 
promoter activity in association with E2F1 (Figure 25). However C/EBP-p30 
alone did not increase PIN1 promoter activity. C/EBP-p42 was able to interfere 
with endogeneous as well as E2F1 mediated transactivation of PIN1 promoter 
activity. 
Figure 25. C/EBP-p42 interferes with transactivation of the PIN1 promoter; C/EBP-
p30 induces PIN1 promoter activity in association with E2F1.  Transient transfection in 
293T cells with a reporter construct of 2.3 kb of the human PIN1 promoter cloned in pGL3 
basic vector and expression plasmids for C/EBPα−p42, C/EBPα−p30 and E2F1. Luciferase 
activities were measured 24 h after transfection and values were normalized by using Renilla 
luciferase PRL0. The results are the means from three independent experiments, and error 
bars represent the standard errors of mean.  
3.2.7 C/EBP-p42 downregulates PIN1 expression  
  Based on our finding that C/EBP-p42 interferes with transactivation of the 
PIN1 promoter (Figure 25), we next asked how C/EBP-p42 regulates PIN1 
mRNA level. We induced the C/EBP-p42 by ß-Estradiol treatment in K562-
C/EBP-p42-ER cell lines for various time intervals. As shown in figure 26, 
wild type C/EBP is able to down regulate PIN1 expression which is opposite to 
the upregulation of PIN1 expression by the p30 form of C/EBP, as shown in 
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figure 20. This demonstrates that C/EBP wild type and its mutant p30 form can 
regulate genes differently.  A recent study has  shown that C/EBP-p30 displays 
transcriptional regulatory roles distinct from the wild type C/EBP protein 
(Wang et al., 2007). This study shows that C/EBP-p30 binds to a unique set of 
genes more strongly than C/EBP-p42. Our finding that PIN1 is regulated 
differently by p42 and p30 reflects the strikingly different biological properties 
of the two protein isoforms. 
Figure 26.  C/EBP-p42 downregulates PIN1 mRNA expression. K562- C/EBP-p42-ER 
cells were induced with ß-Estradiol for respective time points to induce C/EBP-p42 and total 
RNA was isolated at respective time points, proceeded for reverse transcription followed by 
quantitative real time PCR for PIN1. Values were normalized with GAPDH mRNA. The 
results are the means from three independent experiments, and error bars represent the 
standard errors of mean.   
3.2.8 PIN1 protects c-Jun from ubiquitination mediated protein 
degradation 
  PIN1 has shown to regulate the protein degradation of many targets with which 
it interacts (Wulf et al., 2005). Upon JNK activation, PIN1 binds c-Jun that is 
phosphorylated on ser63/73-Pro motifs (Wulf et al., 2001). c-Jun has been 
shown to be be subjected to ubiquitin mediated degradation in a JNK dependent 
manner (Gao et al., 2004). It has been shown previously that ubiquitination 
plays a central role in c-Jun degradation (Fang and Kerppola, 2004). Hence, we 
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hypothesized that PIN1 could play a role in regulating degradation of c-Jun. We 
perfirmed ubiquitination assay in 293T cells by overexpressing c-Jun, PIN1 and 
HA-Ubiquitin constructs. When c-Jun was co-transfected with HA.tagged 
ubiquitin, higher molecular weight ladders were detected in the 
immunoprecipitation with HA antibody that reflects c-Jun ubiqutination (Figure 
27, lane 4). Overexpression of PIN1 prevents the ubiquitination of c-Jun (lane 
5).
Figure 27.  PIN1 protects c-Jun from ubiquitination mediated protein degradation. 
Ubiquitination assay was performed by transfecting 293T cells with the expression plasmids 
for HA-biquitin, c-Jun and PIN1 as indicated, 24 post transfection cells were lysed and c-Jun 
was immunoprecipitated and immunoblot against HA antibody 8upper panel). Membrane was 
stripped and reprobed for c-Jun (lower panel) as control for c-Jun immunoprecipitation
3.2.9 PIN1 regulates c-Jun mRNA level: overexpression of PIN1 
upregulates c-Jun mRNA, while inhibition of PIN1 downregulates c-Jun 
PIN1 increases the transcriptional activity of c-Jun towards cyclin D1 (Wulf et 
al., 2001). Interestingly,  PIN1 is upregulated in  response to  c-Jun 
overexpression (Rinehart-Kim et al., 2000). c-Jun has been shown to bind to its 
own promoter at AP-1 sites and this has been  shown to regulate c-Jun mRNA 
level in a positive manner (Angel et al., 1988). Our data suggests that PIN1 
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prevents the degradation of c-Jun (Figure 27). Based on these findings, we 
hypothesized that PIN1 could have a major role in regulating c-Jun mRNA 
level. We overexpressed PIN1 in Kasumi-6 cells and analysed the c-Jun mRNA 
level by quantitative Real Time PCR. We observed that overexpression of PIN1 
leads to an increase in c-Jun mRNA level (Figure 28A). We next investigated 
the effect of silencing PIN1 on c-Jun mRNA level. We found that silencing 
PIN1 with the inhibitor PiB could downregulate c-Jun levels as observed by 
quantitative Real Time PCR (Figure 28B). 
A.                                                             B. 
Figure 28. Overexpression of PIN1 upregulates c-Jun mRNA, while inhibition of PIN1 
downregulates c-Jun. A) Kasumi-6 cells were transfected with PIN1 expression vector. Total 
RNA was isolated after 24 hr with TRIzol reagent and proceeded for reverse transcription 
followed by quantitative real time PCR for c-Jun. Values were normalized with GAPDH 
mRNA. B) Kasumi-6 cells were treated with PIN1 inhibitor, PiB for various time points and 
proceeded for quantitative real time PCR for c-Jun as described. The results are the means 
from three independent experiments, and error bars represent the standard errors of mean.   
3.2.10 c-Jun blocks the transactivation capacity of C/EBP-p42. 
  It was observed that livers from neonatal C/EBP  knock-out  mice contain 
increased levels of Jun transcripts (Flodby et al., 1996). Another study showed 
that C/EBP could prevent c-Jun from binding to AP-1 site through leucine 
zipper domain interaction (Rangatia et al., 2002). Overexpression of c-Jun was 
shown to block granulopoiesis (Rangatia et al., 2002). These observations show 
how C/EBP and c-Jun are negatively regulating each other. Given the fact that 
c-Jun expression is high in different subtypes of AML including C/EBP
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mutation and c-Jun is able to block DNA binding of C/EBP (Rangatia et al., 
2003), we hypothesised that c-Jun is able to block the transactivation capacity of 
C/EBP. As shown in figure 28, c-Jun is able to inhibit the transactivation 
capacity of C/EBP. This finding shows how overexpressed c-Jun could block 
C/EBP functions.  
Figure 29. c-Jun can block C/EBP-p42 transactivation capacity. Transient Transfections 
were carried out in 293T cells with a reporter construct having minimal TK promoter with 
C/EBP binding sites and expression plasmids for C/EBPα−p42, and c-Jun. Luciferase 
activities were measured 24 hr after transfection and the values were normalized by using 
Renilla luciferase PRL0. The results are the means from three independent experiments, and 
error bars represent the standard errors of mean.  
3.2.11 Overexpression of c-Jun blocks C/EBP-p42 induced granulocytic 
differentiation. 
  It was  shown that downregulation of the proto-oncogene c-Jun by C/EBP is 
critical for granulocytic lineage commitment (Rangatia et al., 2002). Based  on 
our findings that c-Jun is able to block transactivation capacity of C/EBP
(Figure 29) and DNA binding of C/EBP (Rangatia et al., 2003), we 
hypothesized that c-Jun is able to block differentiation induced by C/EBP. We 
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overexpressed C/EBP and c-Jun in U937 cells by AMAXA transfection 
method. Four days after transfection, granulocyte differentiation was assessed 
by FACS analysis for CD15 expression.  The increase in CD15 expression by 
C/EBP was blocked in the presence of c-Jun (Figure 30). c-Jun transfected 
cells were also investigated for CD15 expression; however, no increase in its 
expression was observed (data not shown). 
  
Figure 30. Overexpression of c-Jun blocks C/EBP-p42 induced granulocytic 
differentiation. U937 cells were transfected with c-Jun and C/EBP as indicated and 
granulocytic differentiation was investigated by FACS analysis for CD15 expression. Error 
bars indicate the standard errors of means from three independent experiments.   
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4. Discussion 
4.1 Max as a novel co-activator of myeloid transcription factor C/EBP
  It has become increasingly clear that the interaction of C/EBP with other 
nuclear proteins plays an important role not only in lineage commitment and 
differentiation in the hematopoietic system but also in the pathogenesis of AML. 
Although the lineage commitment decision by C/EBP was proposed by our 
laboratory to involve the functional inactivation of the myeloid master regulator 
PU.1 and/or its co-activator c-Jun through protein–protein interactions (Rangatia 
et al., 2002; Reddy et al., 2002) relatively little is known about how C/EBP  
interacts with other nuclear proteins to regulate gene transcription. The results 
presented in this work provide evidence that Max, a heterodimerization partner 
of Myc, is a novel, functionally and biologically important co-activator of 
C/EBP. C/EBP and Max not only colocalize but also the heterocomplex of 
C/EBP and Max is preferentially formed on the hC/EBP promoter during 
granulocytic differentiation, thereby contributing to increased transactivation 
and differentiation capacity of C/EBP.  
  We used mass spectrometry based proteomic analysis as a means of identifying 
the interacting partners of C/EBP, utilizing immunoprecipitation of C/EBP
from myeloid U937 cells. U937 cells are a good model system for studying 
myeloid differentiation in general, as they are bipotential and can be 
differentiated into the granulocytic lineage by RA. In particular, a threefold 
increase in  C/EBP  protein (above the level of endogenous C/EBP ) in U937 
cells is sufficient for their granulocytic differentiation (Radomska et al., 1998).  
In addition to nine other proteins (see Table 2), we identified Max, an essential 
heterodimerization partner of Myc (Blackwood et al., 1991), as a novel 
interacting partner of C/EBP  in our screen (Figure 12). The discovery of Max 
as a novel C/EBP partner is intriguing because of the role Max plays in 
switching from Myc-Max to Mad-Max heterocomplexes during myeloid 
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differentiation (Ayer and Eisenman, 1993). Of particular importance is the fact 
that transgenic mice carrying an inserted transgene encoding Max have been 
shown to exhibit a 50- to 60-fold elevation of blood neutrophils (Metcalf et al., 
1995). Additionally, Max is an essential heterodimerization partner of Myc 
family members to regulate transcription (Grandori et al., 2000) and c-Myc is an 
important target of C/EBP (Johansen et al., 2001). We confirmed the in vivo
interaction of C/EBP  with Max by immunoprecipitation and showed that the 
basic DNA-binding region of C/EBP  is involved in this interaction, as the 
mutant of C/EBP  (C/EBP  BR3), which lacks the DNA-binding region, could 
not be co-precipitated with Max (Figures 13, 14). C/EBP BR3 carries 
mutations in four amino acids, residues Arg297, Lys298, Arg300 and Lys302 
(Liu et al., 2003). Of these, only Arg300 is expected to contact DNA. Neither 
the BR3 nor the Leu12Val variants bind DNA, suggesting that interaction with 
Max is likely via Arg297, Lys298 and/or Lys302. Arg297 is known to 
participate in the interaction between C/EBP  and E2F (Porse et al., 2001).
Further study is required to pin point the exact amino acids involved in the 
C/EBP and Max interaction. 
  The endogenous C/EBP and Max proteins are not distributed evenly 
throughout the nucleoplasm (Figure 15), but are localized in intranuclear 
structures within the nucleus. In other cell systems, such as pituitary progenitor 
GHFT1-5 cells, C/EBP  has been shown to concentrate at chromatin 
surrounding the centromeres (Schaufele et al., 2001). The observation that 
C/EBP–Max but not Myc–Max remain colocalized during granulocytic 
differentiation (Figure 15) indicates that these intranuclear structures are 
selectively targeted by C/EBP–Max during granulocytic differentiation. We 
observed the occupancy of the hC/EBP promoter by Max in vivo under 
physiological conditions, and recruitment of more C/EBP whereas Max is 
retained on the promoter during granulocytic differentiation. To our knowledge, 
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this is a first report showing occupancy of the hC/EBP promoter by Max in 
vivo. 
  The occupancy of the hC/EBP promoter by Max raises a possibility that Myc 
could also form a part of the complex under physiological conditions, as Max 
requires dimerization with Myc for efficient DNA binding. In fact, it was shown 
that purified Myc-Max heterodimers form stable complexes on the mouse 
C/EBP  promoter that includes the USF binding site (Legraverend et al., 1993).
The USF DNA recognition site CACGTG (which is the same as the E-box, 
occupied by Myc–Max) is found in both the human and the mouse C/EBP  
promoter, and the USF binding site (for HLH-bZIP) is crucial for activation of 
the hC/EBP  promoter by C/EBP (Timchenko et al., 1995). Our colocalization 
and ChIP data (Figures 15 and 17) and the data that C/EBP  is co-precipitated 
with Myc (unpublished observation) support this Myc–Max link. Thus, it is 
tempting to speculate that C/EBP exists in association with the Myc–Max–Mad 
network to regulate differentiation. Given that the C/EBP–Max heterocomplex 
is formed on the hC/EBP promoter, specifically during granulocytic 
differentiation, this would mean that the balance between such complexes, under 
the influence of growth and differentiation signals, could be an important part of 
a molecular switch that is regulating genes important for growth and 
differentiation. By using overexpression studies, we have demonstrated that 
enforced expression of C/EBP and Max in human hematopoietic CD34+ cells 
induce granulocytic differentiation (Figure 18). The role of C/EBP  in the 
transition from CMPs to GMPs in myeloid progenitors has been recently 
characterized (Zhang et al., 2004). The role of Max in inducing granulocytic 
differentiation indicates that Max can activate the myeloid differentiation 
programme either independent of C/EBP or in association with it. In vivo
interaction and retention of C/EBP–Max heterocomplex in myeloid cells 
(Figures 13, 14 and 15) and inhibition of differentiation-inducing capacity of 
C/EBP by silencing of Max using shRNA against MAX in CD34+  cells 
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(Figure 19) suggest that the C/EBP–Max association likely plays an important 
role in this process of myeloid progenitor differentiation. A very recent study 
has shown the role of C/EBP in monopoiesis (Wang et al., 2006). This means 
that the commitment decisions do not necessarily depend upon a single 
transcription factor but, in fact, on a number of cooperating factors. 
  In summary, we conclude that Max is a biologically and functionally important 
and relevant interacting partner of C/EBP and has important co-activator 
functions for C/EBP induced granulocytic differentiation in myeloid 
progenitors. 
Figure 31. Model summarizing the importance of Max as a co-activator of C/EBP in 
the differentiation of myeloid progenitors. During granulocyte differentiation Max-C/EBP
complex occupies human C/EBP promoter. Max acts as a co-activator for C/EBP and 
induces differentiation along the granulocytic pathway. Meanwhile, silencing of Max inhibits 
C/EBP induced differentiation. 
C/EBP
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Max shRNA 
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C/EBP
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4.2 The critical role of PIN1 in AML with C/EBP mutation 
  It is widely accepted that C/EBP functions as a tumor suppressor in multiple 
tissues (Schuster and Porse, 2006). Experimental data from animal models as 
well as AML patient samples suggest that the loss of function or expression of 
C/EBP provides a platform on which AML develops. Even though a number of 
different laboratories have pointed out that C/EBP is mutated in around 9% of 
AML, the mechanism with which the mutated dominant negative form of 
C/EBP i.e., C/EBP-p30 mediates a differentiation block is poorly understood.  
Our findings suggest that C/EBP-p30 might induce PIN1 expression and 
increase the stability of c-Jun, which in turn inhibits the function of wild type 
C/EBP.  
  Initially, it was suggested that the dominant negative effect of C/EBP-p30 is 
the result of heterodimer formation with wild type C/EBP. A recent report 
shows that a C/EBP-p30 with modification in the leucine zipper, which can not 
form heterodimers with C/EBP-p42, still exhibits dominant negative properties 
over the wild type protein (Cammenga et al., 2005). This suggests that rather 
than heterodimerization, regulatory networks activated by C/EBP-p30 could 
play a critical role in its dominant negative function over the wild type protein. 
One recent study showed that C/EBP-p30 has quite distinct functional 
properties compared to the wild type protein (Wang et al., 2007). This study 
showed that C/EBP-p30 binds to a unique set of genes more strongly than 
C/EBP-p42. Mice with targeted disruption of C/EBP-p42 while expressing 
C/EBP-p30 develop leukemia (Kirstetter et al., 2008). This study is of 
particular interest since C/EBP knock-out mice did not develop leukemia even 
though they exhibited a block of granulocytic differentiation (Zhang et al., 
2004). These findings suggest that disruption of wild type C/EBP alone is not 
sufficient to initiate leukemogenesis, but that pathways modulated by C/EBP-
p30 might be critical role in the development of AML.   
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  Our finding that PIN1 is upregulated upon C/EBP-p30 induction is intriguing 
since PIN1 overexpression was shown to act as a critical catalyst that amplifies 
multiple signaling pathways during oncogenesis (Ryo et al., 2003). Also, lack of 
E2F inhibition by C/EBP has been shown to be a key event in AML (Porse et 
al., 2005) and PIN1 has been shown to be regulated by E2F (Ryo et al., 2002).  
Microarray analysis and Western blot analysis identified elevated PIN1 
expression in different subtypes of AML (Figure 21). One possible explanation 
for the upregulation of PIN1 in different AML subtypes could be the fact that 
C/EBP is shown to be downregulated by diverse mechanisms in different 
subtypes of leukemia (Schuster and Porse, 2006) and wild type C/EBP
downregulates PIN1 expression (Figures 25, 26). Also, loss of cell cycle 
regulatory mechanisms in leukemic basts could amplify oncogenic signaling 
pathways and could result in positive regulation of PIN1. Ours is the first report 
showing PIN1 upregulation in human AML. 
  Previous studies showed that PIN1 knock-out mice develop normally and do 
not exhibit any significant phenotype at a young age although they display age 
dependant defects such as retinal atrophy, decreased body weight and testicular 
atrophy (Fujimori et al., 1999; Liou et al., 2002). However, there is no report 
about any phenotypic characters related to hematopoiesis in the PIN1 null 
animals.  The important role of PIN1 in tumorigenesis is underlined by the 
finding that mice lacking PIN1 are resistant to tumorigenesis induced by 
oncogenic Neu or Ras (Wulf et al., 2004).  This study showed that these 
oncogenes need certain pathways in which PIN1 has a key regulatory role. All 
these findings point out that PIN1 is important for oncogenesis in AML as well. 
  The transcriptional activation function of C/EBP is required for the induction 
of granulocytic differentiation (Keeshan et al., 2003). C/EBP-p30 blocks the 
transactivation ability of the wild type C/EBP in a dominant negative manner.  
Our finding that silencing of PIN1 could overcome C/EBP-p30 mediated 
inhibition of C/EBP transactivation (Figure 22) suggests that PIN1 might have 
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an important role in regulating the transcriptional activity of C/EBP. It has 
been previously shown that PIN1 can regulate the transcriptional activity of 
transcription factors such as p53 and p73 (Mantovani et al., 2004; Zheng et al., 
2002). A recent study proposes that C/EBP  could be a PIN1 target (Miller, 
2006). This study point out that several S/T-P motifs in wild type C/EBP could 
be regulated by PIN1 mediated isomerization. Most of the S/T-P motifs in wild 
type C/EBP are present in C/EBP-p30 also.  Even though C/EBP has been 
shown to be phosphorylated, there is no report about PIN1 mediated post 
phosphorylation mechanisms regulating C/EBP function. Further studies are 
needed to explain how PIN1 regulates C/EBP mediated transactivation.  
  It is known that C/EBP-p30 not only fails to induce differentiation but also 
blocks the C/EBP mediated granulocytic differentiation. Based on our findings 
that PIN1 is upregulated in AML (Figure 21) and silencing PIN1 could 
overcome the dominant negative action of C/EBP-p30 over the wild type 
protein in promoter assay (Figure 22), we assessed how silencing of PIN1 
affects myeloid differentiation. Differentiation experiments show that silencing 
PIN1 can overcome the differentiation block of AML blast cells with C/EBP
mutation and Kasumi-6 cells during granulopoiesis (Figure 23). 
  Human AML with C/EBP mutation have a decreased levels of wild type 
C/EBP-p42 and increased levels of C/EBP-p30 (Leroy et al., 2005). Another 
study has shown that C/EBP-p30 dominantly inhibits the wild type protein 
function when the C/EBP-p42 to C/EBP-p30 ratio is less than one (Calkhoven 
et al., 2000). The concentration of certain transcription factors is critical in 
hematopoiesis (Rosenbauer et al., 2004). For example, knocking down PU.1 
below a threshold level has been shown to lead to a preleukemic phase which is 
susceptible to progress to leukemia when additional mutations are present. Even 
though such studies have not been carried out for C/EBP, it seems that a 
similar mechanism might be relevant for C/EBP. In AML with C/EBP
mutation, the wild type C/EBP protein is expressed at lower levels than 
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normal. However, at this level, C/EBP fails to promote differentiation. 
Whether this accounts for haploinsufficency awaits further studies. Our findings 
that silencing PIN1 can upregulate C/EBP-p42 protein levels (Figure 24) and 
lead to myeloid differentiation (Figure 23) suggest that PIN1 might have a major 
role in contributing the differentiation block observed during C/EBP mutation.
  The mechanisms by which C/EBP inhibits cell proliferation seem to differ 
from cell type to cell type. In granulopoiesis, inhibition of E2F activity has been 
proved as the unique mechanism for the anti-mitotic activity of C/EBP (Porse 
et al., 2005; Porse et al., 2001).  E2F1 activates transcription of the c-Myc 
oncogene, which had been shown to block granulopoeisis. C/EBP inhibition of 
E2F1 has been shown to result in the downregulation of c-Myc, leading to 
granulopoeisis (Johansen et al., 2001). Even though the exact mechanism 
through which C/EBP mediates E2F1 repression is not well understood, an 
increasing number of studies suggest that inhibition of E2F1 activity is one of 
the key events orchestrated by C/EBP during the myeloid differentiation 
programme (Rosenbauer and Tenen, 2007). This raises the possibility that other 
E2F1 targets could be also regulated by C/EBP in a similar mechanism as 
observed for c-Myc. Our observation that C/EBP negatively regulates the PIN1 
promoter (Figure 25) as well as PIN1 mRNA (Figure 26) suggests that PIN1 
downregulation by C/EBP is an important event in granulopoiesis. Loss or 
disruption of domains of C/EBP necessary for E2F1 inhibition has been shown 
to result in block of granulocyte differentiation (D'Alo et al., 2003). Mice 
homozygous for a C/EBP knock-in mutation that impairs E2F repression 
develop AML like transformation of the granulocytic lineage (Porse et al., 
2005). At the same time, C/EBP-p30 has been shown to be unable to inhibit 
E2F1 (Porse et al., 2001). Our observation that C/EBP-p30 fails to inhibit 
PIN1, an E2F1 target gene, suggests intrinsic differences between C/EBP wild 
type and C/EBP-p30 in regulating PIN1 expression. Our finding that C/EBP-
p30 can increase the PIN1 promoter activity in association with E2F1 (Figure 
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25) suggests how regulatory networks coordinated by C/EBP-p30 and E2F1 
could play an important role in AML with C/EBP mutation. 
  Previously it has been reported that PIN1 is overexpressed in breast cancer and 
increases the transcriptional activity of c-Jun (Wulf et al., 2001). PIN1 has been 
shown to bind to c-Jun and has been proposed to increase protein stability of c-
Jun (Wulf et al., 2005). Rinehart-Kim et al  has shown that c-Jun overexpression 
can result in increased expression of PIN1 (Rinehart-Kim et al., 2000). These 
studies demonstrate how PIN1 and c-Jun act in a positive feed back loop to 
control each others expression. PIN1 has shown to regulate the protein 
degradation of many targets with which it interacts (Wulf et al., 2005). Our 
finding that PIN1 could prevent c-Jun protein degradation (Figure 27) suggests 
that PIN1 might have a critical role in regulating c-Jun protein turn over. The 
stabilized c-Jun might bind to its own promoter and increase its expression in a 
positive feed back loop.   c-Jun has been shown to be located at the end of signal 
cascades and to have crucial function in diverse mechanisms of oncogenesis 
(Vogt, 2001). The oncogenic role of c-Jun in AML is verified by the finding that 
c-Jun is overexpressed in different subtypes of AML  (Elsasser et al., 2003; 
Rangatia et al., 2003). Leukemic fusion proteins such as BCR-ABL and AML1-
ETO have been shown to induce c-Jun expression through JNK signaling 
pathway (Burgess et al., 1998; Elsasser et al., 2003).  Neonatal livers of  
C/EBP-/-  mice contain increased levels of c-Jun transcript (Flodby et al., 1996). 
Rangatia et al demonstrated that downregulation of c-Jun expression by C/EBP
is critical for granulopoiesis (Rangatia et al., 2002). Their study showed that 
C/EBP inactivates c-Jun via leucine zipper domain interaction. Interestingly, c-
Jun expression is high in AML patient samples with C/EBP mutation (Rangatia 
et al., 2003).  One mechanism for the upregulation of c-Jun expression in AML 
might be the downregulation of C/EBP by different mechanisms.  The ability 
of c-Jun  to block DNA binding of C/EBP (Rangatia et al., 2003) as well as our 
finding that c-Jun is able to inhibit the transactivation capacity and 
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differentiation induced by C/EBP (Figure 29,30) suggests a model in which c-
Jun promotes proliferation and leads to differentiation block by inactivating 
C/EBP. In other words, how c-Jun as well as C/EBP regulate granulopoiesis 
depends upon their relative protein concentration - more C/EBP favors 
differentiation while more c-Jun favors proliferation. 
  In summary, our study identifies PIN1 as an important player that might 
contribute to AML development through the inhibition of C/EBP function. 
Here we demonstrate that PIN1 is upregulated by C/EBP-p30 and that 
silencing of PIN1 was able to overcome the differentiation block mediated by 
C/EBP-p30. Our observations suggest that C/EBP-p30 exerts its dominant 
negative function through regulating PIN1 and c-Jun (Figure 32). Inhibiting 
PIN1 function could provide a novel strategy in the treatment of AML patients.  
Figure  32.  Model depicting the PIN1 mediated dominant negative role of C/EBP-p30
in AML with C/EBP mutation.  C/EBP–p30 cooperates with E2F1 and increase the PIN1 
mRNA levels. PIN1 prevents the protein degradation of c-Jun, which in turn blocks C/EBP
functions and leads to differentiation block. 
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5. Summary 
     Transcription factor CCAAT enhancer binding protein  (C/EBP) is crucial 
for the differentiation of granulocytes. In the present study, we sought to identify 
novel C/EBP interacting proteins in vivo through immunoprecipitation and 
subsequent mass spectrometry based identification. We identified Max, a 
heterodimeric partner of Myc, as one of the interacting proteins of C/EBP in 
our screen. We demonstrate that endogenous C/EBP and Max, but not Myc and 
Max, colocalize in intranuclear structures during granulocytic differentiation of 
myeloid U937 cells. Max enhanced the transactivation capacity of C/EBP as 
shown by promoter assay. Chromatin immunoprecipitation assays reveal 
occupancy of the human C/EBP promoter by C/EBP and Max under retinoic 
acid induced granulocytic differentiation. FACS analyis using granulocytic 
markers shows that enforced expression of Max and C/EBP result in 
granulocytic differentiation of human hematopoietic CD34+ cells. Silencing of 
Max reduced the differentiation inducing potential of C/EBP, indicating the 
importance of the C/EBP–Max interaction in myeloid progenitor 
differentiation. Taken together, our findings demonstrate that Max as a novel co-
activator of C/EBP. 
  Loss of C/EBP expression or function in leukemic blasts contributes to a 
block in myeloid cell differentiation. C/EBP is mutated in acute myeloid 
leukemia (AML). The mutant form of C/EBP, C/EBP-p30 exhibits dominant 
negative properties over the wild type protein. The Peptidyl-prolyl cis/trans 
isomerase, PIN1 is overexpressed in many cancers and has been shown to be 
critical in multiple oncogenic signaling pathways. Here we report that C/EBP-
p30 induces PIN1 mRNA expression as assessed by Real Time RT-PCR in 
K562-C/EBP-p30ER cells. Affymetrix mRNA expression analysis and 
Western blot analysis show that PIN1 is upregulated in patients with AML. 
Silencing of PIN1 by PIN1 inhibitor (PiB) could overcome the dominant 
negative action of the C/EBP-p30 over the C/EBP-p42 transactivation 
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capacity as revealed by promoter assay in 293T cells. C/EBP-p30 induces 
PIN1 promoter activity in association with E2F1. At the same time, wild type 
C/EBP interferes with transactivation of the PIN1 promoter. Also, C/EBP-p42 
downregulates PIN1 mRNA expression as assessed by Real Time RT-PCR in 
K562-C/EBP-p42ER cells. Furthermore, PIN1 inhibition was found to 
upregulate wild type C/EBP protein level and lead to granulocytic 
differentiation in AML blast cells with C/EBP mutation and Kasumi-6 cells. 
PIN1 increases the stability of c-Jun protein via inhibiting its ubiquitination. We 
further demonstrate that overexpression of PIN1 induces c-Jun mRNA 
expression, while inhibition of PIN1 downregulates c-Jun mRNA expression in 
Kasumi-6 cells as analysed by Real Time RT-PCR. Overexpression of c-Jun 
blocks the transactivation and differentiation induced by C/EBP protein as 
shown by promoter assay and FACS anaylsis resepectively.  In conclusion, 
inhibition of PIN1 leads to granulocytic differentiation and suggest PIN1 as a 
novel target in treating AML patients with C/EBP mutation.  
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6. Zusammenfassung 
  Der Transkriptionsfaktor  CCAAT Enhancer Binding Protein   (C/EBP) 
spielt eine entscheidende Rolle bei der Differenzierung neutrophiler 
Granulozyten. In der vorliegenden Arbeit versuchten wir, durch in vivo
Immunopräzipitation mittels auf  Massenspektrometrie basierenden 
Proteomforschungs Techniken neue, mit  C/EBP interagierende Proteine zu 
identifizieren. In unseren Untersuchungen konnten wir Max, ein mit Myc  
Hetero-Dimere bildendes Protein, als eines dieser mit C/EBP interagierenden 
Proteine identifizieren. Hierbei konnten wir zeigen, dass während der 
granulozytären Differenzierung  myeloischer Zellen der U937 Zelllinie 
endogenes C/EBP und Max, jedoch nicht Myc und Max, in intranukleären 
Strukturen co-lokalisiert vorzufinden sind. Max verstärkt dabei die 
Transaktivierungskapazität  von C/EBP wie  durch einen Promoterassay 
gezeigt werden konnte. Der  Chromatin Immunopräzipitations Assay  zeigte 
eine Besetzung des C/EBP Promoters durch C/EBP und Max während der 
All-trans-Retinsäure  induzierten granulozytären Differenzierung. FACS 
Analysen für granulozytische Marker zeigen, das eine verstärkte Expression von 
Max und C/EBP in der granulozytären Differenzierung CD34-positiver 
humaner hämatopoetischer Stammzellen resultieren. Hingegen führt eine 
verminderte Expression von Max zu einer Reduktion des Potentials von C/EBP
eine Differenzierung zu induzieren und deutet damit  auf eine wichtige Rolle der 
Interaktion von C/EBP und Max während der Differenzierung myeloischer 
Vorläuferzellen hin. Zusammenfassend konnten wir Max, infolge unsere 
Ergebnisse, als einen neuen Co-Aktivator des Transkriptionsfaktors C/EBP
identifizieren.   
  Ein Verlust der C/EBP Expression oder seiner Funktion in leukämischen 
Blasten führt zu einer Blockade in der myeloischen Differenzierung. C/EBP
liegt in Akut Myeloischen Leukämien (AML) in mutierter Form vor. Diese 
Mutation, C/EBP-p30, zeigt eine dominant- negative Aktivität  gegenüber dem 
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wild typ Protein auf.  Die Peptidyl-prolyl cis/trans Isomerase, PIN1, ist in vielen 
verschiedenen Tumoren überexprimiert und ist als ein kritischer Faktor in 
multiplen onkogenen Prozessen bekannt.  In der vorliegenden Arbeit zeigen wir 
durch Real Time RT-PCR in K562-C/EBP-p30ER Zellen, dass C/EBP-p30 
die PIN1 mRNA Expression induziert. Affymetrix mRNA Expressions 
Analysen und Western Blot Analysen zeigten, dass bei Patienten mit AML eine 
verstärkte PIN1 Expression vorliegt. Durch einen Promoterassay in 293T Zellen 
konnte gezeigt werden, dass es bei der Inhibierung von PIN1 durch PIN1-
Inhibitor (PiB) eine Überwindung der besagten dominant-negativen Wirkung 
von  C/EBP-p30 auf die Transaktivierungskapazität des C/EBP-p42 Proteins 
erreicht wird. C/EBP-p30 induziert gemeinsam mit E2F1 die PIN1 
Promoteraktivität. Wohingegen das C/EBP-p42 wild typ Protein die 
Promotertransaktivierung beeinträchtigt. Weiterhin reduziert C/EBP-p42 die 
PIN1 mRNA Expression wie durch RT-PCR in K562-C/EBP-p42ER Zellen 
gezeigt werden konnte. Desweiteren konnte gezeigt werden, dass eine Inhibition 
von PIN1 zu einer verstärkten C/EBP Expression und zu granulozytärer 
Differenzierung in AML Blasten mit C/EBP Mutationen und in Kasumi-6 
Zellen führt. PIN1 erhöht die Stabilität des c-Jun Proteins durch Inhibierung 
seiner Ubiquitinierung.  Außerdem  konnten wir in Kasumi-6 Zellen durch Real 
Time RT-PCR zeigen, dass eine Überexprimierung von PIN1 die mRNA 
Expression von c-Jun hochreguliert, wohingegen die c-Jun mRNA Expression 
durch eine Inhibition von PIN1 vermindert wird. In einem Promoterassay und 
durch FACS Analysen konnte gezeigt werden, dass die Überexprimierung  von 
c-Jun  die, durch das C/EBP Protein induzierte, Transaktivierung und 
Differenzierung, blockiert. Zusammenfassend kann gesagt werden, dass die 
Inhibition von PIN1 zur Differenzierung von Granulozyten führt und deutet 
daher  auf eine mögliche Rolle von PIN1 als neues Zielprotein in der Therapie 
von AML Patienten mit C/EBP Mutationen hin.  
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Proteomic discovery of Max as a novel interacting partner of C/EBPa: a Myc/Max/Mad
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The transcription factor CCAAT/enhancer binding protein a
(C/EBPa) is important in the regulation of granulopoiesis and is
disrupted in human acute myeloid leukemia. In the present
study, we sought to identify novel C/EBPa interacting proteins
in vivo through immunoprecipitation using mass spectrometry-
based proteomic techniques. We identiﬁed Max, a heterodi-
meric partner of Myc, as one of the interacting proteins of
C/EBPa in our screen. We conﬁrmed the in vivo interaction of
C/EBPa with Max and showed that this interaction involves the
basic region of C/EBPa. Endogenous C/EBPa and Max, but not
Myc and Max, colocalize in intranuclear structures during
granulocytic differentiation of myeloid U937 cells. Max en-
hanced the transactivation capacity of C/EBPa on a minimal
promoter. A chromatin immunoprecipitation assay revealed
occupancy of the human C/EBPa promoter in vivo by Max and
Myc under cellular settings and by C/EBPa and Max under
retinoic acid induced granulocytic differentiation. Interestingly,
enforced expression of Max and C/EBPa results in granulocytic
differentiation of the human hematopoietic CD34þ cells, as
evidenced by CD11b, CD15 and granulocyte colony-stimulating
factor receptor expression. Silencing of Max by short hairpin
RNA in CD34þ and U937 cells strongly reduced the differentia-
tion-inducing potential of C/EBPa, indicating the importance of
C/EBPa–Max in myeloid progenitor differentiation. Taken to-
gether, our data reveal Max as a novel co-activator of C/EBPa
functions, thereby suggesting a possible link between C/EBPa
and Myc–Max–Mad network.
Leukemia (2006) 20, 2137–2146. doi:10.1038/sj.leu.2404438;
published online 2 November 2006
Keywords: C/EBPa; proteomics; Myc–Max–Mad network; mass
spectrometry; differentiation
Introduction
Hematopoietic differentiation proceeds in a largely irreversible
fashion and the role of transcription factors in regulating
hematopoiesis has been well documented. This is particularly
true for CCAAT/enhancer binding protein a (C/EBPa), one of the
lineage-speciﬁc transcription factors that is essential for commit-
ment to and development of the granulocytic lineage.1,2 Recent
data have indicated that C/EBPa may also regulate hematopoie-
tic stem cell activity3 and act as a tumor suppressor gene in
acute myeloid leukemias (AMLs), indicating an important role
for C/EBPa in the control of cellular proliferation in vivo.4
Inactivation of C/EBPa is an important event in AML, and
ectopic overexpression of C/EBPa leads to differentiation and
growth arrest in AML.5 It is therefore suggested that C/EBPa has a
crucial role in regulating the balance between cell proliferation
and differentiation, which is crucial for lineage commitment of
any cell type. These ﬁndings and data from our laboratory
indicate that for AML to develop, the activity of C/EBPa must be
curbed by either mutations or antagonistic protein–protein
interactions.
C/EBPa can form protein–protein interactions with other bZIP
and non-bZIP factors. Among them, c-Jun and PU.1,6,7 E2F,
p21, and cyclin-dependent kinases CDK2 and CDK4 have been
well characterized.8–10 Thus, it has become increasingly clear
that like most proteins, C/EBPa might not work alone, but in
association with other factors regulates gene transcription.
However, studies involving protein–protein interactions of
C/EBPa at the global proteomic level are lacking. We therefore
took advantage of high-throughput proteomics by mass spectro-
metry (LC-MS/MS) to identify proteins that speciﬁcally associate
with C/EBPa in vivo. In our screen, Max was identiﬁed as a
novel interacting partner of C/EBPa in addition to other new and
known partners of C/EBPa.
Max is a member of the basic region-helix–loop–helix-leucine
zipper protein that belongs to a network of transcription factors,
which includes the Myc and Mad families of protein (commonly
referred to as a Myc–Max–Mad network).11 The Myc–Max–Mad
proteins can affect different aspects of cell behavior, including
cell cycle, proliferation and differentiation, by modulating
distinct target genes.12–15 Max can form a homo- or a
heterodimer and bind speciﬁcally to E-box DNA elements in
target promoters (consensus CACGTG).16,17 To function as
transcriptional regulators, the members of the Myc and Mad
families must heterodimerize with Max. Whereas Myc–Max
activates transcription, Mad–Max and Mnt–Max repress tran-
scription.18–20 Indirect evidences to the fact that C/EBPa could
be a part of the Myc–Max–Mad network do exist in the
literature.21,22 However, no direct evidence has been reported
so far.
In this study, we have characterized the role of Max as an
interacting partner of C/EBPa. We show that Max is an important
co-activator of C/EBPa and the stable silencing of Max inhibits
the differentiation-inducing potential of C/EBPa. C/EBPa and
Max not only colocalize but also the heterocomplex is
preferentially formed on the human C/EBPa (hC/EBPa) promoter
in vivo during granulocytic differentiation, thereby contributing
to increased transactivation and differentiation capacity of
C/EBPa.
Received 26 April 2006; revised 10 September 2006; accepted 14
September 2006; published online 2 November 2006
Correspondence: Professor Dr G Behre, Bone Marrow Transplantation
Unit, State Center for Cell and Gene Therapy, Clinic Internal Medicine
IV, Martin-Luther-University, Ernst-Grube-Str. 40, 06097 Halle,
Germany.
E-mail: gerhard.behre@medizin.uni-halle.de
Leukemia (2006) 20, 2137–2146
& 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00
www.nature.com/leu
Materials and methods
Transfection of human hematopoietic CD34þ
progenitors
Human CD34þ hematopoietic cells were selected, using a
magnetic CD34 selection kit system (Milteny Biotec, Bergisch,
Gladbach, Germany), from small aliquots of leukapheresis
products collected from either healthy donor or a patient
undergoing stem/progenitor cell collection after granulocyte-
colony stimulating factor treatment for non-hematologic malig-
nancy at Klinikum Krollwitz Hospital Halle, Germany, following
their informed consent. After magnetic selection, more than
85% of the cells expressed the CD34 antigen. An aliquot
containing 5 105 CD34þ cells was cultured in Iscove’s
modiﬁed Dulbecco’s medium with 20% heat-inactivated fetal
calf serum, 100 ng/ml Flt3-ligand, 100 ng/ml of stem cell factor,
100 ng/ml thrombopoietin, 100 ng/ml of interleukin-6 (IL-6) and
50ng/ml of IL-3, 100U/ml penicillin/streptomycin and 2mM
L-glutamine. The cells were transfected with various expression
constructs using AMAXA nucleofection technology essentially
as described by the manufacturer and analyzed for CD11b and
CD15 expression by ﬂow cytometry.
Cell lines, antibodies and treatments
Human myeloid cell lines U937 and K562-ER-C/EBPa were
cultured under standard conditions. b-Estradiol and retinoic acid
(RA) (Sigma-Aldrich, Munich, Germany) were used at a
concentration of 1–5mM and 106 M, respectively. The anti-
bodies used in this study were purchased from Santa Cruz
(Heidelberg, Germany); for C/EBPa, SC-61 (14AA), SC-9315
(N-19) Max, SC-765 (C-124) and c-Myc, SC-42 (C-33) and
Molecular Probes, Gmbh, Karlsruhe, Germany).
Immunoprecipitation and immunoblotting
The immunoprecipitation (IP) was performed from 500–1000 mg
nuclear extracts of U937 cells in an IP buffer (50mM Tris pH 7.5,
150mM NaCl, 0.5% NP-40, 0.25% sodium deoxycholate),
followed by washing in the buffer (50mM Tris pH 7.5, 0.1%
NP-40, 0.05% sodium deoxycholate) with respective antibodies
(Santa Cruz) and the corresponding IgGs as controls. A Western
blot analysis was used to conﬁrm the identity of immuno-
precipitated and/or co-precipitated proteins as described pre-
viously.23 Alternatively, the immunocomplexes were incubated
with urea lysis buffer for further proteomic analysis.
Proteomic analysis: two-dimensional gel
electrophoresis and protein identiﬁcation by mass
spectrometry
The proteomics methodology was used essentially as described
recently by our group.34
Transient transfections using AMAXA and effectene
Effectene transfection reagent (Qiagen, Gmbh, Hilden, Ger-
many) and lipofectamine (Invitrogen, Gmbh, Karlsruhe, Ger-
many) were used for transient transfections according to the
manufacturer’s instructions. Transient transfections were carried
out with minimal promoter/luciferase construct, which has been
derived from an oligo 50-GATCCAGATTGCGCAATCG-30 by
self-annealing, followed by ligation into a BamHI site of the
thymidine kinase (TK) promoter and co-transfected with expres-
sion plasmids for hC/EBPa, Renilla Luciferase-null and/or Max as
described.23 The Nucleofector kit (AMAXA, Gmbh, Cologne,
Germany) was used essentially as described by the manufac-
turer. A 5mg portion of plasmid DNA constructs was used for
each transfection and the transfection efﬁciency was analyzed
using a plasmid with eGFP marker (2 mg). For CD34þ and U937
cells, nucleofector solution kits used were VPA-1003 and VCA-
1003 with nucleofection programs U-08 and V-01, respectively.
The voltages are automatically adjusted according to the
program and are essentially 110V AC with a frequency of
50–60Hz and a power consumption of 16VA/fuse.
Immunoﬂuorescence and ﬂow cytometry
U937 cells (3 105), under uninduced condition or induced
with RA (Sigma-Aldrich), were cytocentrifuged on glass slides
with coverslips, ﬁxed using 1:1 methanol/acetone and permea-
bilized using 0.3% Triton X. After blocking in PBG (0.5% BSA,
0.045% Fish–gelatin in phosphate-buffered saline) containing
5% FBS, the ﬁxed cells were incubated with anti-C/EBPa (anti-
goat; Santa Cruz), anti-Max (anti-rabbit; Santa Cruz) and anti-
Myc (anti-mouse; Santa Cruz) antibodies, followed by incuba-
tion with corresponding Alexa Fluor 488 chicken anti-goat,
Alexa Fluor 594 chicken anti-rabbit and anti-mouse IgG
secondary antibodies (Molecular Probes) and 40,60-diamidino-
2-phenylindole dihydrochloride (DAPI, 1 mg/ml) for 15min. The
cells were mounted in aqueous mounting medium and the
images were acquired and analyzed using a ﬂuorescence
microscope ( 100,  60). Flow cytometry was performed for
CD11b, CD14 and CD15 expression on Bectin Dikinson ﬂow
cytometer, using the supplied analysis software.
Quantitative real-time PCR
RNA isolation from CD34þ and U937 cells, transfected with
different expression constructs, by TRIZOL (Invitrogen, Ger-
many) was followed by cDNA synthesis using standard
conditions. Equal amount of cDNA was taken for a subsequent
quantitative real-time PCR (Q-RT-PCR) using the Quantitech
SyBR Green PCR kit (Qiagen, Germany) in a Rotor-Gene RG-
3000 (Corbett Research, Sydney, Australia). The delta ct value
(Dct) was then calculated from the given ct value by the formula
Dct¼ ctsamplectcontrol). The fold change was calculated as fold
change¼ 2Dct. The following primer sequences were used:
myeloperoxidase (MPO), 50-TCG GTA CCC AGT TCA GGA
AG-30 (forward) and 50-CCA GGT TCA ATG CAG GAA GT-30
(reverse); neutrophilelastase (NE), 50-TGC TCA ACG ACA TCG
TGA TT-30 (forward) and 50-CTC ACG AGA GTG CAG ACG
TT-30 (reverse); GCSFR, 50-AAG AGC CCC CTT ACC CAC TAC
ACC ATC TT-30 (forward) and 50-TGC TGT GAG CTG GGT CTG
GGA CAC TT-30 (reverse); CD14, 50-CAA CTT CTC CGA ACC
TCA GC-30 (forward) and 50-CCA GTA GCT GAG CAG GAA
CC-30 (reverse).
Chromatin immunoprecipitation assay
Logarithmically growing and differentiating U937 cells
(B1 108 cells) were ﬁxed with formaldehyde (ﬁnal concentra-
tion 1% (v/v)) in serum free RPMI-1640 medium, at 41C for 1 h.
Glycine was added to a ﬁnal concentration of 0.125M to stop
cross-linking. Fixed cells were pelleted by centrifugation and
sequentially washed and sonicated (ﬁve times for 20 s each) to
make soluble chromatin. Samples of total chromatin were taken
at this point to use as a positive control in the PCRs (input
chromatin). Antibodies against C/EBPa, Max and c-Myc were
used overnight at 41C. After serial elution, washing and cross-
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link reverse, the samples were extracted twice with phenol/
chloroform and precipitated with ethanol overnight in the
presence of 20mg glycogen as a carrier. DNA fragments were
recovered by centrifugation, resuspended in ddH2O, and used
for PCR ampliﬁcation. For detection of immunoprecipitated
C/EBPa promoter region, two primers, forward (50-ACCGC
TACCGACCACGTGGGCG-30) and reverse (50-AGCACCTC
CGGGTCGCGAATGG-30), speciﬁc for a 280 bp region in the
cellular C/EBPa promoter that encompasses the C/EBP site were
used for Q-RT-PCR ampliﬁcation.
Results
Identiﬁcation of Max, a heterodimeric partner of Myc,
as a novel interacting protein of C/EBPa
To identify interacting proteins of C/EBPa in vivo under
physiological conditions on a global level, we applied
proteomics technique coupled with mass spectrometry using
the IP conditions of endogenous C/EBPa from myeloid U937
cells as a model system.
Under our experimental conditions, we could speciﬁcally
immunoprecipitate endogenous C/EBPa from the nuclear
extracts of U937 cells (Figure 1a) and co-immunoprecipitate
other endogenous proteins (as positive controls) such as c-Jun
and CDK4 (Figure 1b and data not shown) that were not present
in the isotype IgG control. Immunocomplexes were further
processed for proteomic analysis. The protein spots excised from
the 2D gels (Figure 1c, spots are numbered) were identiﬁed by
MALDI-TOF MS. Additionally, the individual bands were
excised from Coomassie/silver-stained sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gels (Figure 1d) and pro-
cessed for LC-MS/MS. From both screens, we were able to reveal
the identity of 10 proteins by MS, which speciﬁcally interact
with C/EBPa (Table 1). Among these proteins, we identiﬁed Max
as one interacting partner of C/EBPa. C/EBPa was also identiﬁed
by MS analysis of the corresponding band (Figure 1d), thereby
serving as a control for our experimental setup. Proteins in other
bands could not be determined because of the poor quality of
the spectrum. The discovery of Max as a novel C/EBPa partner is
intriguing because of the role Max plays in switching of the
complexes during myeloid differentiation.24 We therefore
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Figure 1 MS-based proteomics identiﬁes proteins speciﬁcally interacting with C/EBPa in vivo after its immunoprecipitation from myeloid U937
cells. (a) C/EBPa IP from nuclear extracts of U937 cells and a corresponding immunoblotting (IB) with anti-C/EBPa antibody to conﬁrm the
presence of C/EBPa protein in the IP complex. In vitro-translated C/EBPa (ivt, lane 1) was used as a positive control in the Western blot. (b) C/EBPa
IP and corresponding IB with anti-c-Jun antibody to show endogenous proteins co-precipitated with C/EBPa. ivt c-Jun was used as a positive
control for c-Jun. (c) Silver-stained 2D gels showing proteins speciﬁcally interacting with C/EBPa. C/EBPa was immunoprecipitated from nuclear
extracts using anti-C/EBPa antibody (anti-rabbit; Santa Cruz) and the immunocomplex separated in the ﬁrst dimension by pH 4–7 IPGphor strips
followed by their separation in the second dimension using 12% SDS-PAGE. As a speciﬁcity control, we used immunoprecipitation with IgG under
similar conditions. (d) Silver-stained SDS-PAGE gels after IP with anti-C/EBPa and anti-IgG. The bands were excised and peptide mixture after
trypsin digestion was run on a reverse-phase high-pressure liquid chromatography and the peptides identiﬁed by MALDI-TOF-TOF (Applied
Biosystems, Darmstadt, Germany).
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selected Max for further functional and biological characteriza-
tion.
C/EBPa and Max interact in a cellular setting:
conﬁrmation of proteomics data
To conﬁrm the observed interaction of Max with CEBPa by an
alternative technique, we performed reciprocal immunoprecipi-
tation. Our results demonstrate that C/EBPa interacts with Max
and vice versa (Figure 2a) in vivo, and thereby conﬁrm proteomic
results. It is important to note that for the same amounts of nuclear
extracts used (5 and 10mg) as input controls, the levels of the two
transcription factors are dramatically different, which is likely due
to Max being more stable than C/EBPa.
BR3 region of C/EBPa is involved in its interaction with
Max
To investigate the protein domains that might be involved in
C/EBPa–Max interaction, we performed co-immunoprecipita-
tion studies using different mutants of C/EBPa as shown. C/EBPa
and its various mutants (kind gift from Dr Alan Friedman;
Figure 2b) were transiently transfected into 293 cells, and co-
transfected with an expression plasmid for Max (a kind gift from
Dr Dirk Eick) containing a carboxy-terminal HA tag.25 Max was
then immunoprecipitated from nuclear extracts using anti-Max
antibody. The associated complexes were assayed by immuno-
blotting for C/EBPa using anti-C/EBPa antibody. Our results
demonstrate that C/EBPa could be co-immunoprecipitated when
IP was performed using anti-Max antibody in samples in which
wild-type C/EBPa: wild-type Max, GZ/LZ C/EBPa: wild-type
Max and L1-2V C/EBPa: wild-type Max were coexpressed
(Figure 2c, lanes 4, 3, 1, respectively). However, C/EBPa could
not be co-immunoprecipitated in immunoprecipitated samples
in which basic region mutant BR3-C/EBPa: wild-type Max was
co-expressed (Figure 2c, lane 2). We also show that Max could
be speciﬁcally immunoprecipitated (as controls) with immuno-
blot for Max using anti-HA antibody (Figure 2c, lower panel).
The relative expression of C/EBPa mutants was the same (data
not shown). These data show that the basic region of C/EBPa is
involved in its interaction with Max in a cellular setting.
Furthermore, we observed that wild-type Max and its basic
region mutants have the same ability to interact with C/EBPa
(Supplementary Figure S1a and b).
C/EBPa and Max colocalize
Given the fact that C/EBPa and Max are nuclear transcription
factors and the observation that they interact in vivo, we next
investigated the localization of these proteins by indirect
immunoﬂuorescence in myeloid U937 cells. We observed both
endogenous C/EBPa and Max to be localized in intranuclear
structures (Figure 3a) and the overlay of the two images shows
Table 1 MS results of the proteins interacting with C/EBPa: MALDI-TOF Reﬂex III (Bruker Daltonics) and LC-MS/MS
Spot no. Acc. no. Protein name Score Mol. wt. pI Sequence coverage
1 A42611 Max 85 21.029 5.64 53
2 Q9UP93 Macrophin1 fragment 95 620 (full) 5.27 35
3 M2OM_Hum Mitochondrial2-oxoglutarate/malate carrier protein 65 34.08 9.92 37
8 A47213 Beta fodrin 68 146.55 5.18 14
12 Q96QA8 RPGR interacting protein 1 88 147.33 5.47 14
13 Q9P1U9 ZNF45 71 80.44 9.0 16
15 FAHUAA Actinin 1 238 103.48 5.22 31
16 Q9UKD2 60 S ribosomal protein 74 127.60 7.68 29
* NMD3A N-methyl-D-aspartate receptor 3A * 126.67 * *
* SMADIP1 Smad interacting protein 1 * 137.84 * *
Abbreviations: C/EBPa, CCAAT/enhancer binding protein a; LC-MS/MS, liquid chromatography-coupled tandem mass spectrometry.
Proteins identiﬁed by MALDI-TOF mass spectrometry and LC-MS/MS from 2D gels and normal SDS-PAGE gels (represented as *), respectively.
Acc. no: SwissProt. protein accession numbers; Mol. wt: apparent molecular weight; pI: isoelectric point of the protein.
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Figure 2 In vivo interaction of C/EBPa with Max conﬁrmed by
reciprocal IP involves the DNA-binding domain of C/EBPa. (a)
Reciprocal IPs: C/EBPa and Max were immunoprecipitated (IP C/EBPa,
IP Max) from nuclear extracts of U937 cells by incubation with anti-C/
EBPa and anti-Max, respectively, and respective IgG as controls. The blot
was ﬁrst probed with anti-C/EBPa antibody, stripped and reprobed with
anti-Max antibody. (b) Basic region of C/EBPa is involved in its
interaction with Max. Schematic representation of wild-type hC/EBPa
and different mutants used in this study. TAD, transactivation domains 1
and 2; BR, basic region; LZ, leucine zipper domain; HLH, helix–loop–
helix. (c) hC/EBPa wild type and its mutants were transfected in 293T
cells and co-transfected with wild-type Max expression plasmid. At 24h
post-transfection, the nuclear extracts were prepared and IP of Max
performed for the samples followed by immunoblot for C/EBPa or Max
using anti-C/EBPa and HA antibodies, respectively.
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that both proteins colocalize in these intranuclear structures
(Figure 3a,panel 4; yellow signal).
C/EBPa–Max but not Myc–Max remains colocalized
during granulocytic differentiation of myeloid U937
cells
We next investigated the effect on C/EBPa–Max colocalization
when the cells were triggered for granulocytic differentiation by RA
for 24h. We observed intranuclear staining with C/EBPa and Max
antibodies, and the overlay of the two images shows that both
proteins remain colocalized even after RA treatment of the cells
(Figure 3b, panel 4; yellow signal). As Max is associated with Myc,
we also analyzed their localization in U937 cells. We observed
that endogenous Myc–Max colocalize in the nucleus under
uninduced condition (Figure 3a, panels 5 and 6). On the other
hand, no intranuclear c-Myc signal could be detected after RA
treatment (Figure 3c, panel 4; only green signal from Max). We
next investigated the expression of c-Myc, Max and C/EBPa before
and after RA treatment from various fractions (whole-cell lysates,
nuclear fraction (NF) and cytoplasmic fraction (CF)) by Western
blotting, using speciﬁc antibodies (Figure 3d). Our results revealed
that the c-Myc protein level was drastically decreased in all the
three fractions (Figure 3d, upper and lower panels) by RA.
However, C/EBPa was undetectable in the CF and slightly
increased in the NF by RA when analyzed by immunoblotting.
Dot blot analysis revealed the presence of CEBPa in the CF as well.
This indicates that the concentration of C/EBPa in the CF is quite
low, so as not to be detected by immunoblotting (data not shown).
Max, on the other hand, was relatively unchanged under induced
and uninduced conditions. These data demonstrate that retention/
colocalization of C/EBPa–Max, and not Myc–Max heterocom-
plexes, in the nucleus might be important events during
granulocytic differentiation of U937 cells.
Max enhances the ability of C/EBPa to transactivate a
minimal thymidine kinase promoter
To investigate the functional importance of C/EBPa–Max
interaction and their colocalization, we performed transient
transfection assays in the ﬁbroblast 293T and the myeloid U937
cells using a minimal TK promoter containing two CCAAT
binding sites cloned upstream of the luciferase reporter gene.
Transfection of a Max expression construct signiﬁcantly en-
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Figure 3 Endogenous C/EBPa-Max but not Myc–Max remains colocalized during granulocytic differentiation of U937 cells. (a) Indirect
immunoﬂuorescence staining for C/EBPa (anti-goat; Santa Cruz), Max (anti-rabbit; Santa Cruz) and Myc (anti-mouse, Santa Cruz) using respective
conjugated secondary antibodies (Molecular Probes). U937 cells were cytocentrifuged on glass slide cover slips, ﬁxed with methanol/acetone,
permeabilized with 0.3% Triton X stained with respective antibodies (Alexa Fluor, Molecular Probes) and DAPI. The morphology of the cells was
visualized under ﬂuorescence microscope (X60–100). Colocalization is demonstrated by the yellow signals. Indirect immunoﬂuorescence staining
for (b) C/EBPa-Max and (c) Myc–Max using conjugated antibodies (Molecular Pobes) in U937 cells after RA treatment. (d) Immunoblot analysis
showing expression of c-Myc, Max and C/EBPa under RA-induced and uninduced conditions from various fractions. Blots were stripped and
reprobed with speciﬁc antibody. Upper panel: whole-cell lysates; NF: nuclear fraction; CF: cytoplasmic fraction.
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hanced the ability of C/EBPa to transactivate a minimal TK
promoter containing two CCAAT binding site in a dose-
dependent manner (Figure 4a). In control experiments, no effect
of Max on C/EBPa activity was observed when promoter with no
CCAAT binding sites was used, whereas C/EBPa alone was able
to transactivate the minimal promoter construct ninefold. Similar
results were obtained with myeloid U937 cells (Figure 4b).
Interestingly, co-transfection studies with the human B2200bp
C/EBPa promoter (which has intact E-box site and no CCAAT
site) revealed that C/EBPa alone was unable to transactivate the
promoter, whereas, co-transfection of Max led to a signiﬁcant
increase in the promoter activity (Figure 4c). It is important to
point out that Max itself does show some activation.
C/EBPa and Max associate in vivo: a Myc–Max–Mad
link
To further elucidate the mechanism by which Max augments the
transcriptional activity of C/EBPa, we hypothesized that Max
might associate with the hC/EBPa promoter in vivo because
similar to C/EBPa, Max also possesses a DNA binding basic
region. To test this possibility, we performed quantitative
radioactive and non-radioactive chromatin immunoprecipita-
tion (ChIP) in U937 cells (Figure 5). Chromatin was subjected to
IP by using antibodies directed against C/EBPa, c-Myc and Max.
The presence of C/EBPa promoter was detected by amplifying a
promoter region using primers speciﬁc for a 280 bp region in the
C/EBPa promoter that encompasses the CACGTG site (com-
monly referred to as E-box; Figure 5a). The E-box is conserved in
the human and mouse C/EBPa promoter (Figure 5a). We
observed that under normal physiological conditions (unin-
duced), endogenous c-Myc and Max appeared on C/EBPa
promoter and there was undetectable endogenous C/EBPa
occupancy on the hC/EBPa promoter (Figure 5b). IP using an
isotype-matched IgG served as a negative control.
We next investigated the affect on heterocomplex formation
at the hC/EBPa promoter upon differentiation by RA. We
observed that both Max and C/EBPa appeared on C/EBPa
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Figure 4 Max enhances the transactivation capacity of C/EBPa in transient transfection assays. (a, b) Transient transfection in 293T and U937 cells
with a reporter construct of a minimal TK promoter with CEBP binding sites only p(CEBP)2TK and expression plasmids for hC/EBPa and Max. pTK
(without CEBP sites) was used as control. Luciferase activities were measured 24h after transfection and the values normalized by using Renilla
luciferase PRL0. (c) Transient transfection in 293T cells with a 2200bp hC/EBPa promoter showing increased promoter activation when Max is co-
expressed. Histogram on the right shows promoter activation by hC/EBPa on a minimal promoter, used as a positive control in this experiment.
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promoter and in fact, more C/EBPa was associated with the
promoter in the context of chromatin upon differentiation
induction (Figure 5c, lane 4). The amount of Max bound to
the promoter was fairly constant. DNA recovery was quantiﬁed
as a percentage of the total input chromatin (lanes 5–7). Q-RT-
PCR conﬁrmed this observation and the histograms shown
represent the average values from two independent experiments
(Figure 5c, lower panel). A promoter without the CACGTG site,
such as GAPDH promoter (Figure 5d), was used as a negative
control for C/EBPa and Max occupancy and hTERT promoter
(Figure 5e) as a positive control for Myc and Max interaction on
the CACGTG site (E-box). The size of the DNA fragments before
and after sonication is also shown (Figure 5f). Thus, C/EBPa and
Max associate in vivo in the context of chromatin and are
associated together more strongly on the hC/EBPa promoter
when the cells are induced towards granulocytic differentiation.
Overexpression of Max and C/EBPa promotes
differentiation along the granulocytic pathway
in human hematopoietic CD34þ cells
We next asked whether interaction of Max with C/EBPa is
biologically important for C/EBPa functions. Hence, we
performed overexpression studies using three different experi-
mental systems: human hematopoietic CD34þ cells, estradiol-
inducible K562-C/EBPa-ER cells and U937 cells. Our results
revealed that overexpression of Max or C/EBPa alone in CD34þ
cells leads to a signiﬁcant increase in the proportion of
CD11bþ (Figure 6a, dot plot 44 vs 20%) and CD15þ
(Figure 6a, dot plot 29 vs 13%) cells compared with the
mock-transfected control, respectively. The histograms represent
the average values from three different experiments, and the
viable cell count data (Trypan blue staining) under different
conditions are also shown for days 1 and 4 (Figure 6b). Q-RT-
PCR in these cells revealed increased GCSF receptor expression
(Figure 6c). Similar results were observed with U937 and K562-
C/EBPa-ER cells (Supplementary Figure S2a and data not
shown). The morphology of the cells was observed to correlate
with the surface marker expression (Supplementary Figure S2b).
Q-RT-PCR in U937 cells for various granulocytic/ monocytic
markers was also performed to complement the ﬂuorescence-
activated cell sorting results (Supplementary Figure S2c).
Stable silencing of Max by short hairpin RNA reduces
the differentiation-inducing capacity of C/EBPa in
human hematopoietic CD34þ cells
If Max is a biologically important co-activator of C/EBPa,
silencing of Max should inhibit differentiation induction by
C/EBPa. To address this, we performed RNA interference
experiments in human hematopoietic CD34þ cells and
myeloid U937 cells (Supplementary Figure S2d) by using short
hairpin RNA (shRNA) against Max (cat. no. RHS1764-9690535;
Open Biosystems, Heidelberg, Germany) and control shRNA
(cat. no. RHS1707; Open Biosystems). Cells were transfected
with expression plasmids for C/EBPa alone and/or co-expressed
with shRNA against Max, control shRNA, and the cells cultured
in media containing puromycine. After selection, the cells were
analyzed for granulocytic differentiation, using CD15 expres-
sion as a marker. Our results revealed that C/EBPa alone induces
granulocytic differentiation (CD15þ ) ﬁve- to six-fold as
compared with the mock-transfected CD34þ (Figure 6d).
Coexpression of Max shRNA led to a signiﬁcant decrease in
CD15þ population (about twofold), whereas control shRNA
did not lead to any signiﬁcant reduction in CD15þ population
(Figure 6d, compare histograms). The reduction of Max protein
level with shRNA was conﬁrmed by Western blotting and Max
shRNA did not affect the expression of C/EBPa (Figure 6e). In
conclusion, we propose a model shown as Figure 6f. Thus, Max
is important for C/EBPa-mediated effects on granulocytic
differentiation and might have an important role in stem cell
development.
GAPDH
Antibodies M
ax
C/
EB
Pα
in
pu
t
Ig
G
M
ax
M
yc
in
pu
t
Ig
G
hTERT
Antibodies
0.97
0.98
0.99
1
1.01
1.02
1.03
1.04
1.05
1.06
= -RA
= +RA
Av
er
ag
e 
Δc
t v
al
ue
IP C/EBPα IP Max
HUMPROM. SEQ CTACCGACCACGTGGGCGCGGGGGCGAC -251
MOUSPROM. SEQ CCACGGACCACGTGTGTGCGGGGGCGAC
Uninduced RA induced
Antibodies
Input
hCEBPa
0.
25
 %
5 
%
10
 %
1      2 3      4 5      6     7
C/
EB
Pα
M
ax
C/
EB
Pα
M
ax
C/
EB
Pα
M
ax
M
yc Ig
G
hC/EBPa
Antibodies Input
1 2 3 4
a
b
c
d
e
f
Figure 5 Max is associated at the hC/EBPa promoter in vivo and
Max–C/EBPa associate strongly during granulocytic differentiation. A
ChIP assay was performed on logarithmically growing and RA-treated
U937 cells, and the precipitated chromatin was PCR-ampliﬁed using
speciﬁc primers. (a) Comparison of the human and mouse C/EBP
promoters encompassing a consensus CACGT sequence, commonly
referred to as E-box and known to be occupied by MycþMax
heterodimers. (b) In vivo occupancy by Myc and Max at the hC/EBPa
promoter in logarithmically growing and (c) by Max-C/EBPa in RA-
treated U937 cells. Input: Radioactive and Q-RT-PCR performed on
total chromatin. The histograms beneath show the Q-RT-PCR average
Dct values from two independent experiments normalized with the
control sample. (d, e) ChIP assay using GAPDH promoter and human
TERT promoter as controls with a non-radioactive RT-PCR. (f) Sheared
DNA from U937 cells following 10 sonication pulses shows the
optimal size range for IP (200–1000 bp). Lane: 1, unsheared; lanes: 2
and 3, sheared DNA.
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Discussion
It has become increasingly clear that interaction of C/EBPa with
other nuclear proteins plays an important role not only in
lineage commitment and differentiation in the hematopoietic
system but also in the pathogenesis of AML. Although the
lineage commitment decision by C/EBPa was proposed by our
laboratory to involve the functional inactivation of the myeloid
master regulator PU.1 and/or its co-activator c-Jun through
protein–protein interactions,6,7 relatively little is known about
how C/EBPa interacts with other nuclear proteins to activate
gene transcription. The results presented in this article provide
evidence that Max, a heterodimerization partner of Myc, is a
novel, functionally and biologically important co-activator of
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CEBPa. C/EBPa and Max not only colocalize but also the
heterocomplex is preferentially formed on the hC/EBPa promo-
ter during granulocytic differentiation, thereby contributing to
increased transactivation and differentiation capacity of C/EBPa.
We used MS-based proteomic analysis as a means of
identifying the interacting partners of C/EBPa, utilizing IP of
C/EBPa from myeloid U937 cells as a model system. U937 cells
are a good model system for studying myeloid differentiation in
general, as they are bipotential and can be differentiated into
granulocytic lineage by RA and in particular, with respect to the
functions of C/EBPa, as a threefold level of C/EBPa protein
(above the level of endogenous C/EBPa) in U937 cells is
sufﬁcient for their granulocytic differentiation.26 In addition to
nine other proteins (see Table), we identiﬁed Max, an essential
heterodimerization partner of Myc,16 as a novel interacting
partner of C/EBPa in our screen (Figure 1). The discovery of Max
as a novel C/EBPa partner is intriguing because of the role Max
plays in switching of the complexes during myeloid differentia-
tion.24 Of particular importance is the fact that transgenic mice
carrying an inserted transgene encoding Max have been shown
to exhibit a 50- to 60-fold elevation of blood neutrophils.27
Additionally, Max is an essential heterodimerization partner of
Myc family members to regulate transcription11 and c-Myc is an
important target of C/EBPa.26 We conﬁrmed the in vivo
interaction of C/EBPa with Max by IP technique and showed
that the basic DNA-binding region of C/EBPa is involved in this
interaction, as the mutant of CEBPa (C/EBPa BR3), which lacks
DNA-binding region, could not be co-precipitated with Max
(Figure 2). C/EBPa BR3 carries mutations in four amino acids,
residues Arg297, Lys298, Arg300 and Lys302.28 Of these, only
Arg300 is expected to contact DNA. Neither the BR3 nor the
Leu12Val variants bind DNA, suggesting that interaction with
Max is likely via Arg297, Lys298 and/or Lys302. Arg297 is
known to participate in the interaction between C/EBPa and
E2F.8 Further study is required to pin point the exact amino acid
involved in the C/EBPa and Max interaction.
The endogenous C/EBPa and Max proteins are not distributed
evenly throughout the nucleoplasm (Figure 3), but are localized
in intranuclear structures within the nucleus. These structures
represent, presumably, centromeres, which are chromosomal
structures associated with intranuclear chromosome positioning
and cell cycle regulation. Interestingly, C/EBPa is associated
with cell cycle regulation.29,30 In other cell systems, such as
pituitary progenitor GHFT1-5 cells, C/EBPa has been shown to
concentrate at chromatin surrounding the centromeres.31 The
observation that C/EBPa–Max but not Myc–Max remain
colocalized during granulocytic differentiation (Figure 3) in-
dicates that these intranuclear structures (centromeres) are
selectively targeted by C/EBPa–Max during granulocytic differ-
entiation. We observed the occupancy of the hC/EBPa promoter
by Max in vivo under physiological conditions, and recruitment
of more C/EBPa whereas Max is retained on the promoter during
granulocytic differentiation. It is possible that the C/EBPaMax
heterocomplex regulates the balance of acetylated histones to
modify chromatin structure at the hC/EBPa promoter and lead to
transcriptional activation, as was shown by our results. In fact,
TIP60, a histone acetyl transferase, was identiﬁed as an
interacting partner of C/EBP to regulate histone acetylation at
the hC/EBPa promoter a in an alternative approach (Bararia
et al., manuscript submitted for publication). To our knowledge,
this is a ﬁrst report showing occupancy of the hC/EBPa promoter
by Max in vivo.
The occupancy by Max of the hC/EBPa promoter raises a
possibility that Myc could also form a part of the complex
under physiological conditions, as Max requires dimerization
with Myc for efﬁcient DNA binding. In fact, it was shown that
puriﬁed MycþMax heterodimers form stable complexes on
the mouse C/EBPa promoter that includes the USF binding
site.21 The USF DNA recognition site CACGTG (which is the
same as the E-box, occupied by Myc–Max) is found in both
the human and the mouse C/EBPa promoter, and the USF
binding site (for HLH-bZIP) is crucial for activation of the hC/
EBPa promoter by C/EBPa.32 Our colocalization and ChIP
data (Figures 4 and 5) and the data that C/EBPa is co-precipitated
with Myc IP (unpublished observation) support this Myc–Max
link. Thus, it is tempting to speculate that C/EBPa exists in
association with the Myc–Max–Mad network to regulate differ-
entiation under cellular settings. Given that the C/EBPa–Max
heterocomplex is formed on hC/EBPa promoter, speciﬁcally
during granulocytic differentiation, this would mean that the
balance between such complexes, under the inﬂuence of
growth and differentiation signals, could be an important part
of a molecular switch that is regulating genes important for
growth and differentiation.
By using overexpression studies, we have demonstrated that
enforced expression of C/EBPa and Max in human hematopoie-
tic CD34þ cells induces granulocytic differentiation. The role
of C/EBPa in the transition from CMPs to GMPs in myeloid
progenitors has been recently characterized.3 The role of Max in
inducing granulocytic differentiation indicates that Max can
activate myeloid differentiation program either independent of
C/EBPa or in association with it. In vivo interaction and retention
of C/EBPa–Max heterocomplex in myeloid cells (Figures 2, 4
and 5) and inhibition of differentiation-inducing capacity of
C/EBPa by stable silencing of Max using shRNA against MAX in
CD34þ cells (Figure 6) suggest CEBPa–Max association likely
plays an important role in this process of myeloid progenitor
differentiation. A very recent data from Alan Friedman’s group
has shown the role of C/EBPa in monopoiesis.33 This means that
the commitment decisions do not necessarily depend upon a
single transcription factor but, in fact, on a number of
cooperating factors.
In summary, we conclude that Max is a biologically
and functionally important and relevant interacting partner of
Figure 6 Overexpression of Max induces differentiation along granulocytic pathway in human hematopoietic CD34þ cells. (a) The expression
plasmids for human C/EBPa and Max were transfected into human hematopoietic CD34þ cells by using AMAXA technology. The surface
expression of CD11b and CD15 was analyzed by ﬂow cytometry at day 4. The histograms underneath represent data from three different
experiments. (b) Trypan blue staining, showing the number of viable cells under different conditions. (c) Q-RT-PCR for GCSF receptor expression
under the conditions shown from two experiments. (d) Stable silencing of Max by shRNA inhibits C/EBPa-induced differentiation in human
hematopoietic CD34þ cells. The expression plasmid for human C/EBPa and/or expression Arrest shRNA_Max plasmid (Open Biosystems) were
transfected into human hematopoietic CD34þ cells or U937 cells by using the AMAXA technology. After their selection in puromycine, the cells
were analyzed for the surface expression of CD15 by ﬂow cytometry and the data shown as dot plot with percentage of positive cells representative
of one experiment. shRNA control was also used in all the experiments and is shown. The histograms represent the data from three different
experiments. (e) A Western blot for Max using anti-Max antibody showing silencing of Max at the protein level by shRNA_MAX. The blot was
stripped and reprobed with C/EBPa antibody. (f) Model, a summary of our data showing the importance of Max as a co-activator of C/EBPa in the
differentiation of myeloid progenitors. Enforced expression of Max and CEBPa induces differentiation along the granulocytic pathway, and stable
silencing of Max inhibits CEBPa-induced differentiation.
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C/EBPa and has important co-activator functions for C/EBPa-
induced granulocytic differentiation in myeloid progenitors.
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